The Role of the SUPRMAM1 Locus in Responses to Ionizing Radiation and Susceptibility to Mammary Tumors by Griner, Nicholas B
University of Massachusetts Amherst
ScholarWorks@UMass Amherst
Open Access Dissertations
5-13-2011
The Role of the SUPRMAM1 Locus in Responses
to Ionizing Radiation and Susceptibility to
Mammary Tumors
Nicholas B. Griner
University of Massachusetts Amherst, ngriner@mcb.umass.edu
Follow this and additional works at: https://scholarworks.umass.edu/open_access_dissertations
Part of the Cell Biology Commons
This Open Access Dissertation is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in
Open Access Dissertations by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.
Recommended Citation
Griner, Nicholas B., "The Role of the SUPRMAM1 Locus in Responses to Ionizing Radiation and Susceptibility to Mammary
Tumors" (2011). Open Access Dissertations. 392.
https://scholarworks.umass.edu/open_access_dissertations/392
 
 
 
 
THE ROLE OF THE SUPRMAM1 LOCUS IN RESPONSES TO IONIZING 
RADIATION AND SUSCEPTIBILITY TO MAMMARY TUMORS 
 
 
 
 
 
A Dissertation Presented 
 
By 
 
NICHOLAS B. GRINER 
 
 
 
Submitted to the Graduate School of the 
University of Massachusetts Amherst in partial fulfillment 
of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
May 2011 
 
Program in Molecular and Cellular Biology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by Nicholas B. Griner 2011 
 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
THE ROLE OF THE SUPRMAM1 LOCUS IN RESPONSES TO IONIZING 
RADIATION AND SUSCEPTIBILITY TO MAMMARY TUMORS 
 
 
 
 
 
 
 
A Dissertation Presented 
 
By 
 
NICHOLAS B. GRINER 
 
 
 
Approved as to style and content by: 
 
 
 
 
_____________________________________________ 
D. Joseph Jerry, Chair 
 
 
_____________________________________________ 
Sallie Smith Schneider, Member 
 
 
_____________________________________________ 
Steven J. Sandler, Member 
 
 
_____________________________________________ 
Alan Schneyer, Member  
 
 
_____________________________________________ 
          Barbara A. Osborne, Director 
                                 Program in Molecular and Cellular Biology 
 
 
 
 
 
 
 
 
 
DEDICATION 
 
 
 
 
 
 
 
To my parents:  Mark and Suzanne Griner 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ACKNOWLEDGMENTS 
 
 I wish to acknowledge and thank first my advisor D. Joseph Jerry.  He has been 
instrumental in my graduate training and has taught me much in the scientific process.  In 
addition, Joe has been incredibly supportive of my work and in guiding me through the 
Ph.D process.  I also would like to thank all of the current and past members of the Jerry 
lab.  This includes Ellen Dickinson, Luwei Tao, Haoheng Yan, Mary Hagen, Amy 
Roberts, Karen Dunphy, Erick Perez, Cindy Kane, Trevor Baptiste, Shannon Compton 
and Linda Hill.  Jeff Kane’s technical skills were incredibly helpful in much of this 
research.  Many thanks to Brooke Bentley and Sharon Marconi for their histology work.  
A special thanks to Kelly Gauger and other members of the Smith-Schneider lab 
including Matthew Carter for insightful and entertaining conversations.  I would also like 
to thank my committee members, Alan Schneyer, Steve Sandler and Sallie Smith-
Schneider for their helpful comments and suggestions in my research.  Special thanks to 
Sallie for sharing her lab space with me.  Thanks to all of the members of the PVLSI 
including members of the mouse facility who were instrumental for many of these 
studies.  Finally, a special thanks to Lesley Mathews for her advise and overall support 
throughout my graduate school experience.   
  
 
 
 
 
 v
 ABSTRACT 
 
THE ROLE OF THE SUPRMAM1 LOCUS IN RESPONSES TO IONIZING 
RADIATION AND SUSCEPTIBILITY TO MAMMARY TUMORS 
 
MAY 2011 
 
NICHOLAS B. GRINER, B.S., UNIVERSITY OF WASHINGTON 
 
Ph.D., UNIVERSITY OF MASSACHUSETTTS, AMHERST 
 
Directed by:  Professor D. Joseph Jerry 
 
 Loss of p53 function can lead to a variety of cancers, including breast cancer.  
Mice heterozygous for the p53 gene (designated Trp53+/-) develop spontaneous 
mammary tumors, but this depends on the strain background and has been linked to a 
locus on chromosome 7 (designated SuprMam1).  Mammary tumors are common in 
BALB/c-Trp53+/-females, but are rare in C57BL/6-Trp53+/- mice. Prevalence of genomic 
instability appears to contribute to the phenotype as loss of heterozygosity (LOH) is 
significantly more common among tumors arising in BALB/c-Trp53+/- mice compared to 
C57BL/6J-Trp53+/- mice. This increased LOH in BALB/c-Trp53+/- tumors was shown to 
be due to recombination events.  The BALB/c strain has been shown to have a deficiency 
in non-homologous end joining (NHEJ) of DNA double strand breaks (dsb), however, 
this does not account for the increase of LOH events in tumors.  Our hypothesis was that 
BALB/c-Trp53+/- mice are more susceptible to mammary tumors due to impaired 
Homologous Recombination Repair (HRR) leading to LOH. Using the COMET assay, 
we demonstrate that dsbs persist longer in BALB/c-Trp53+/- mouse embryonic fibroblasts 
(MEFs) compared to C57BL/6J-Trp53+/- MEFs.  Similarly, co-localization of H2AX and 
 vi
the homologous recombination protein RAD51 remain at dsbs longer in BALB/c-Trp53+/- 
MEFs compared to C57BL/6-Trp53+/- MEFs.  Palb2, a gene that lies within the 
SuprMam1 interval and has been shown to contribute to heritable breast cancer, was 
chosen as an initial candidate gene.  No coding SNPs or expression differences of Palb2 
were found in the mammary glands between the two strains.   Additional fine mapping 
and use of a filtering criteria in the SuprMam1 region yielded an additional 34 candidate 
genes.  We demonstrate no significant differences in any of these genes in whole 
mammary glands and primary mammary epithelial cells between the two strains.  Finally, 
using a congenic mouse strain, we demonstrate the lack of irradiation (IR) sensitivity 
alleles within the SuprMam1 region.  These results suggest a possible defect in HRR in 
the BALB/c strain that is unlikely related to Palb2.  The gene or genes respsonsible for 
increased mammary tumor incidence in the BALB/c-Trp53+/- remain to be identified. 
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 CHAPTER 1 
INTRODUCTION TO BREAST CANCER RISK ALLELES AND THEIR ROLE 
IN DNA DOUBLE-STRAND BREAK REPAIR 
 Breast cancer is one of the leading causes of cancer death in women behind only 
lung cancer (Jemal et al., 2009).  Despite decreases in breast cancer related deaths, this 
disease still leads to the death of over 40,000 women a year.  Advances in treatment and 
early detection continue to lead to better prognoses.  However, the incidence rate has 
continued at a steady rate, accounting for 23% of total cancer cases.  Identification of risk 
factors on the molecular level would provide new and valuable insights towards the 
treatment of this devastating disease.    
Most of the understanding of the mechanisms of susceptibility to breast cancer 
comes from the identification of hereditary risk alleles. BRCA1 and BRCA2  are two 
genes identified in the mid-1990’s by positional cloning (Miki et al., 1994; Wooster et al., 
1994).  Individuals that are BRCA1 or BRCA2 carriers inherit one defective copy of the 
gene.  Inheriting a defective copy of either gene is rather rare, a population carrier 
frequency of <0.1% (Peto et al., 1999b).  Although these high penetrance susceptibility 
alleles impart a 10-20 fold risk in breast cancer incidence, there are other non-genetic 
modifiers of risk that can increase or decrease the relative risk for BRCA1/2 carriers.  
These include age of menarche (Kotsopoulos et al., 2005), pregnancy (McLaughlin et al., 
2007), breastfeeding (Jernstrom et al., 2004) and oral contraceptives (Narod et al., 2002) 
among others.  Individuals that carry disease causing BRCA1 or BRCA2 alleles 
commonly have mutations that lead to inactivation of the encoded proteins mostly due to 
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truncations.  Families with a history of breast cancer are now genetically screened for 
mutations in BRCA1/2 due to the risk these alleles impart.  
P53 has a role in many cell pathways including apoptosis, cell cycle control and 
DNA repair (Vogelstein et al., 2000).  Its role in suppressing tumors is critical and has 
been termed the “Guardian of the Genome”.  P53 appears to be critical in determining 
whether a cell initiates apoptosis or DNA repair following genomic damage.  Studies 
have identified a large number of TP53 mutations in breast cancer establishing its role in 
breast cancer development (Gasco et al., 2003; Soussi et al., 2006).  Many of these 
mutations are within the DNA binding domain which is critical for its function in DNA 
double-strand break repair (Dudenhoffer et al., 1999).  This role in dsb repair appears to 
be separate from other transcription-dependent roles of p53 (Gatz and Wiesmuller, 2006).  
Individuals who inherit germline mutations of TP53 develop Li-Fraumeni syndrome 
characterized by increased rates of many cancers including brain tumors, soft tissue 
sarcomas, leukemia and breast cancer.  Nearly 100% of Li-Fraumeni women will develop 
some kind of cancer (Chompret et al., 2000).  In addition, many of the TP53 mutations 
identified in Li-Fraumeni patients are localized in the DNA binding region of the protein 
(Petitjean et al., 2007).  The role of p53 in HRR appears to be in repressing it (Akyuz et 
al., 2002d; Wiesmuller et al., 1996).  Specifically, studies have shown that p53 represses 
hyper-recombination in response to replication fork stalling, thus acting as fidelity control 
(Janz and Wiesmuller, 2002).   These studies highlight the significance of p53 and its role 
in dsb repair within the breast.          
Together, BRCA1, BRCA2 and TP53  make up approximately 16% of hereditable 
risk for breast cancer (Peto et al., 1999a).  The discovery of other high penetrance alleles 
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over the years has proven fruitless.  This leaves approximately 80% of hereditary risk to 
unknown genes.  Some groups have suggested a polygenic model where multiple 
common genes impart a small risk and together may account for the remaining 80% 
familial risk (Ponder, 2001b).  Accordingly, multiple low penetrance alleles that have 
been identified including CHEK2, PALB2, BRIP1, NBN, RAD50 and ATM (Nevanlinna 
and Bartek, 2006; Erkko et al., 2008; Rahman et al., 2007b; Seal et al., 2006; Swift et al., 
1991; Heikkinen et al., 2006).  Individuals who inherit a defective copy of any of these 
genes have a two to fourfold risk for breast cancer compared to a 10-20 fold with 
BRCA1/2.  While these alleles are more frequent in the population than the high 
penetrance BRCA1 and BRCA2 risk alleles, they are still relatively uncommon (~0.6%).  
Interestingly, all of these genes are involved in dsb repair.  Bi-allelic loss of PALB2 and 
BRIP1 causes Fanconi Anemia similar to bi-allelic loss of BRCA2 (Xia et al., 2007a).  In 
addition, bi-allelic loss of ATM and NBS1 lead to the genomic instability-like diseases 
ataxia-telangectasia and Nijmigen breakage syndrome, respectively.  Thus, breast cancer 
susceptibility is the phenotype in mono-allelic genotypes with these low penetrance 
alleles and more severe diseases in bi-allelic genetic backgrounds.   
Genome-wide association studies have identified additional low penetrance 
modifiers (Easton et al., 2007b; Ahmed et al., 2009; Cox et al., 2007; Hunter et al., 2007).  
Initial studies identified CASP8, TFGB1 and TNF as potential risk alleles.  Additional 
studies identified an additional six loci including FGFR2 ,TOX3, MAP3K1 and LSP1 
(Easton et al., 2007a).  Interestingly enough, two of the SNPs used to identify regions of 
the genome linked to breast cancer susceptibility are localized within non-coding regions.  
How these SNPs may be affecting breast cancer risk is unknown.  Despite the recent 
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identification of these low penetrance alleles, estimates still put the percentage of 
unknown hereditary breast cancer risk alleles at 70% (Szpirer and Szpirer, 2007) (Figure 
1.1).  Much work is still to be done to identify additional candidate risk alleles and their 
respective roles in hopes for development of novel treatments towards breast caner.   
The DNA repair pathway is highly linked to breast cancer susceptibility.  This is 
primarily due to all breast cancer hereditary risk alleles being involved in DNA repair.  In 
fact, they are all involved in one subset of DNA repair, double-strand break repair.  This 
makes sense as cells from breast tumors show increased chromosomal breaks after 
irradiation suggesting these cells are deficient in DNA repair (Parshad and Sanford, 
2001).  Normal DNA replication can also lead to dsbs if the polymerase complex runs 
into bulky lesions during processing (Arnaudeau et al., 2001).  The two primary methods 
to resolve this break are nonhomologous end joining (NHEJ) and homologous 
recombinational repair (HRR) (Figure 1.2).  The choice of pathway is largely determined 
by the cell cycle stage when the damage is encountered (Rothkamm et al., 2003).  If the 
double strand break occurs during the G1/G0 phase, NHEJ will be the preferred method.  
HRR is the method of choice during S-phase when sister chromatids are present to act as 
a template.  NHEJ is traditionally thought to be a non-conservative repair pathway as 
some genetic material is lost during the process.  HRR is considered a conservative repair 
as a sister chromatid or homologous chromosome is used as a template resulting in no 
loss of DNA sequence.  There are many proteins involved in the correct sequence of 
events for each pathway.  A group of proteins termed the MRN complex consisting of 
MRE11, RAD50 and NBS1 are the first to recognize the double strand break (Valerie and 
Povirk, 2003a).  In addition, immediately following DNA damage, ATM phosphorylates 
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the histone H2A which acts as a scaffold for the accumulation of DNA repair proteins.  
H2AX thus acts a marker for the DNA damage response that can be measured in cells.  
The MRN complex binds to the ends of the broken DNA and proceeds to perform end 
processing and act as a scaffold.  Next, RAD51 is loaded onto the DNA forming 
nucleoprotein filaments.  RAD51 with cofactors acts as a recombinase and initiates the 
strand invasion into the complimentery homologous chromosome or sister chromatid 
(Hartlerode and Scully, 2009).  After branch migration and repair synthesis has occurred, 
RAD51C and XRCC3 resolve the holiday junction and ligate the ends together.  Another 
form of HRR can occur that requires RAD52 instead of RAD51.  This non-conservative 
pathway directly anneals the ssDNA overhangs at the break site leading to degradation of 
the overhangs and loss of genetic material (Ahmad et al., 2008).   
The other major DSB repair pathway is NHEJ.  This process first involves the 
binding of KU70/80 to the ends of the broken DNA (Burma et al., 2006).  DNA protein 
kinase (DNA-PKcs) then forms a complex with KU70/80 and the catalytic sub-unit is 
activated.  XRCC4 and DNA Ligase IV (LIG4) are then recruited and the break is 
directly annealed.  Mammalian cells have been shown to primarily employ the NHEJ 
pathway to repair double strand breaks (Shrivastav et al., 2008).  There appears to be both 
an error-prone and error-free NHEJ pathway that relies on how “clean” the double strand 
break is (Zhang and Powell, 2005).  Error-free NHEJ appears to be regulated at least 
partly by BRCA1 and its ability to suppress the more error-prone pathway (Zhuang et al., 
2006).  BRCA1 also appears to direct the cell towards the HRR pathway over the error-
prone microhomology directed NHEJ (Baldeyron et al., 2002).   
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 Loss of TP53 is the most commonly mutated gene observed in tumors (Hollstein 
et al., 1994).  Attempts to create mouse models of Li-Fraumeni disease have proven 
difficult due to genetic strain differences (Backlund et al., 2001a).  C57BL/6 mice 
heterozygous for p53 have extremely low rates of mammary tumors.  In contrast, 
BALB/c mice heterozygous for p53 develop mammary tumors at frequencies similar to 
Li-Fraumeni individuals (Kuperwasser et al., 2000c).  Previous work in our lab 
performing genetic linkage mapping studies identified a region on chromosome 7, termed 
SuprMam1, that showed significant linkage to the mammary tumor phenotype 
(Blackburn et al., 2007e) (Figure 1.3).  Dmbt1 was identified as a candidate due to 
expression differences observed between the strains.  Protein expression for DMBT1 was 
also shown to be significantly reduced in breast tissue from women with breast cancer 
compared with cancer-free controls.  However, the Dmbt1 gene is located at the boundary 
of  the SuprMam1 region suggesting other genes within the interval may explain strain 
differences in mammary tumor incidence.  A separate quantitative trait loci (QTL) was 
also mapped proximal to SuprMam1 and is believed to contain dominant modifier(s) to 
mammary tumor latency (Koch et al., 2007).  The gene or genes responsible for 
mammary tumor latency differences between these two strains is still unknown. 
 The goal of this dissertation was to use the BALB/c Trp53+/- mouse strain as a 
model for breast cancer to answer the following questions.   
 Is the BALB/c-Trp53+/- strain defective in DNA dsb repair?   
 Are there DNA repair genes within the SuprMam1 interval that could explain 
increased mammary tumor latency in the BALB/c Trp53+/- strain? 
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 Are there significant SNP differences within the SuprMam1 region of the BALB/c 
Trp53+/- strain? 
 Are there corresponding expression differences in the BALB/c Trp53+/- strain? 
 Are there alleles within the SuprMam1 region that contribute to the increased IR 
sensitivity in the BALB/c Trp53+/- strain? 
 The following dissertation describes the strategies and ultimately the answers to 
these questions and the implications in breast cancer risk. 
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Figure 1.1 Diagram describing the known genes involved in hereditary risk for 
breast cancer and the percentage of risk they impart. 
Adapted from Szpirer C et al. 
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Figure 1.2 Overview of the DNA double-strand break pathways in mammalian cells.  
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DMBT1
Figure 1.3  Published linkage maps of mammary tumor susceptibility in the 
BALB/c Trp53+/- strain.  Mtsm1 describes a linked region containing dominant 
modifiers while SuprMam1 contains recessive modifiers to mammary tumor 
susceptibility.   
Adapted from Blackburn A et al, 2007 and Kock et al, 2007 . 
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 CHAPTER 2 
DIFFERENCES IN DNA REPAIR BETWEEN THE MOUSE STRAINS C57BL/6 
AND BALB/C ON A TRP53+/- GENETIC BACKGROUND 
Introduction 
Loss of heterozygosity (LOH) is a critical step in the pathway towards 
tumorigenesis (Donahue et al., 2006).  LOH for p53 is a very common event in breast 
cancer (Johnson et al., 2002).  Studies have demonstrated that tumors from BALB/cMed- 
Trp53+/- mice have increased LOH compared to tumors from C57BL/6-Trp53+/- mice  
(Blackburn et al., 2004c) and the increase LOH is inherited as an autosomal dominant 
trait in the F1 progeny.  Analysis of mammary tumors from F1 and N2 backcross mice 
demonstrated that LOH occurred via a recombination pathway. These data suggest that 
the increased LOH in BALB/c tumors may be a genetic defect in double strand break 
repair.   
Non-homologous end-joining (NHEJ) and homologous recombination repair 
(HRR) are the major pathways used to repair DNA double-strand breaks. Although NHEJ 
is considered a non-conservative repair pathway as genetic material is loss during this 
process, it is believed to be the more prominent dsb repair pathway in mammalian species 
(Lieber et al., 2003).  In contrast, the HRR pathway uses sister chromatids or homologous 
chromosomes as templates to fill in dsbs.  This results in the loss of no genetic material 
and is the preferred pathway in stem cells (Francis and Richardson, 2007).  Interestingly, 
most breast cancer risk alleles have prominent roles in the HRR pathway (summarized 
in Figure 1.2) implicating the importance of this pathway in genetic stability. 
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In addition to the observed increased LOH in BALB/c tumors, other lines of 
evidence suggest differences in DNA double-strand break repair may be responsible for 
mammary tumor susceptibility in BALB/c-Trp53+/- mice.  The BALB/c strain is known 
to have a defect in NHEJ due to a polymorphism in Prkdc, the gene that encodes DNA-
PKcs.  Defects in NHEJ will likely increase the rates of HRR, possibly leading to 
inappropriate recombination and LOH.  To test these hypotheses, we implemented 
multiple methods in hopes to establish clear differences in DNA dsb repair between these 
two strains.  We first used a novel DNA double-strand break repair assay that 
distinguishes HRR from NHEJ.  We also used immunofluorescence as a technique to 
analyze the amount of proper localization of DNA repair proteins following DNA 
damage.  A cell viability assay was implemented to test the sensitivity of MEFs from 
both strains to DNA damage inducing drugs.  Finally, we used the Comet assay that 
measures unrepaired DNA following DNA damage.   
Methods 
Cell Culture Media:   
MEFs were grown in alpha MEM media (Fisher Scientific) with 10% FBS, AB/AM 
(Gibco), 2mM glutamine, 15 μg/ml gentamycin (Gibco) and 8 μg/ml tylocin (Gibco).  
Uterine rinse for MEF isolation consisted of PBS, AB/AM, 1.25% Fungizone (Gibco), 15 
μg/ml gentamycin (Gibco) and 8 μg/ml tylocin (Gibco).  Collagenase mixture contained 
0.2% collagenase (Gibco) desolved in alpha MEM, AB/AM, 1.25% Fungizone, 15 μg/ml 
gentamycin (Gibco) and 8 μg/ml tylocin (Gibco).   
P53 LOH genotyping: 
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Early passage MEFs from both strains were grown in standard growth medium.  At 
approximately 90% confluency, the cells were passed at a 1:2 ratio.  DNA was isolated 
from each plate at every passage by a standard protocol.  P53 amplification was 
performed using PCR and the following primers, 5’-TATACTCAGAGCCGGCCT-3’, 
5’-ACAGCGTGGTGGTACCTTAT-3’, 5’-CTATCAGGACATAGCGTTGG-3’.  
Completed PCR reactions were then run out on a 1% agarose gel and stained with 
ethidium bromide.  The amount of each amplified amplicon was measured using a 
standard phosporimager and the accompanying software.   
Isolation of mouse embryonic fibroblasts (MEFs): 
Female pregnant mice (day 14 of pregnancy) were sacrificed and their uterus were 
removed.  Each individual embryo was removed from a uterine chamber and the head 
was removed using a sterile razor blade.  Any reddish mesenchymal internal tissue was 
scraped out of the embryo before being minced up with scissors.  This tissue was then 
mixed with 0.2% collagenase (Gibco) in alpha MEM media with antibiotics but without 
serum.  This was incubated for 30 minutes at 37oC.  Cells were pelleted by centrifugation 
at 1500 RPM for 5 minutes.  Each batch of cells was washed with alpha MEM and 
pelleted again.  Each separate fetus was then plated on a T-75 plate.  At least 6 plates 
worth of cells were combined to create a batch of homogenous mouse embryonic 
fibroblasts for each strain and genotype. 
Double-strand break repair assay: 
Rates of NHEJ and HRR were determined by transfection of different combinations of 
plasmids depending on which pathway was being assessed.  Briefly, 8 x 105 cells were 
mixed with a combination of a meganuclease expression vector (pCMV-I-SceI) and 
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either EJ-EGFP or HR-EGFP/3′EGFP constructs, corresponding to NHEJ and HRR, 
respectively.  Control samples contained a mixture of pCMV-I-SceI and wtEGFP 
plasmid.    Transfection was performed by AMAXA (Lonza) nucleofection procedure 
A23.  Tweny four hours following transfection, the percentage of GFP positive cells was 
determined by flow cytometry.  50,000 cells were counted per sample.  The percentage of 
repair was calculated by the percentage of GFP positive cells divided by the transfection 
efficiency.  Three transfection replicates were performed for each experiment and 
averaged.  Statistical analysis was performed by student t-test.   
Immunofluorescence:   
MEFs were seeded 500,000 cells/60 mm dish containing coverslips.  Plates were 
irradiated with 2.5 Gy for the appropriate time points.  Next, 500 μl of 3.7% 
formaldehyde was added for 7 minutes to fix cells.  Formaldehyde was removed followed 
by washing cells 2 times with PBS.  500 μl of .05% TritonX in PBS was added to the 
cells for 7 minutes on ice.  TritonX was removed and cells were washed once with PBS.  
Using tweezers, coverslips were removed from well, dipped in PBS/.05% Tween and 
then placed coverslips on an upside down top of a 24-well plate with the cells facing up.  
25 μl of primary antibodies (RAD51 1:100 and γH2AX 1:1000) diluted in PBS with 5% 
goat serum was added to the coverslip, covered and incubated at 37 degrees for 1 hour.  
Coverslips were then placed back into 24 well plate and washed with PBS 3 times, 5 
minutes each.  Secondary antibodies were then diluted in PBS (1:1000 for Alexafluors 
488 and 594) with 5% goat serum and 25 μl was added to each coverslip and incubated 
for 40 minutes at 37 degrees.  Coverslips were placed back into 24 well plate and wash 3 
times, 5 minutes each.  DAPI was diluted in PBS (1:5000) and incubated with coverslips 
 14
in 500 μl for 5 minutes.  Coverslips were washed 2 more times with PBS and mounted on 
microscope slides with about 7 μl of Mowiol with 2.5% Dabco.  Slides were then placed 
in the dark overnight and were washed the next day to remove salts off coverslips.  Slides 
were analyzed by immunofluoresence microscope at 60X magnification.  The number of 
cells were counted by DAPI staining and the percentage of H2AX and RAD51 positive 
cells was determined (“positive” indicates two or more foci per cell). 
MTS assays (MMC and Camptothecin treatment): 
MEFs were seeded in 96-well plates so that the control groups for each genotype  
produced similar proliferation rates (previously determined).  2500 cells/well for B6 
Trp53+/+, 1850 cells/well for B6 Trp53+/-, 5000 cells/well for Balb/c Trp53+/+ and 3250 
cells/well for Balb/c Trp53+/- were seeded into a 96-well plate with 100 µl of α-MEM 
media with serum.  The next day, media was replaced with media containing 
concentrations of either MMC or Camptothecin and cells were incubated for three days at 
37 degrees.  At the end of the third day, 20 µl of MTS reagent (Promega CellTiter 96) 
was dispensed into each well and plates were incubated for two and a half hours at 37 
degrees.  Plates were then read on a plate reader at 490 nm wavelength and data points 
(triplicate) from each dose was plotted relative to control.   
Comet Assay: 
MEFs for each genotype were seeded into 60 mm plates at a density of 100,000 cells.  
Six hours later, plates were irradiated with 5 Gy and incubated for ~15 hours at 37 
degrees.  Cells were then trypsinized, spun down and resuspended in 10 µl PBS.  75 µl of 
low melting agarose was mixed with each cell suspension and pipetted onto pre-coated 
microscope slides (slides were processed by first removing the oil surface by methanol 
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flame followed by dipping half the slide into 1% agarose and dried overnight).  A 
coverslip was applied and the slides were placed in 4 degrees to allow agarose to harden.  
Another 80 µl of low melt agarose was applied to each slide and coverslip placed on top.  
Following this, coverslips were removed and slides were placed in coplin jars with 
enough lysis buffer to cover the slides.  Jars were placed at 4 degrees for 2 hours to allow 
lysis of cells.  Slides were then placed into gel electrophoresis boxes with enough buffer 
to cover slides and incubated for 20 minutes at room temperature to allow DNA to 
unwind.  Electrophoresis for 30 min. was performed at 24 volts and 300 milliamperes 
(volume of buffer was adjusted to achieve 300 mAmps).  Slides were removed from 
boxes and neutralization buffer was added (~ 1 mL) for 5 minutes.  This was repeated 
two more times and then slides were washed briefly with dH2O.  Slides were stained with 
DAPI for 5 min., washed again with dH2O and coverslips were put into place.  Pictures of 
slides were taken at 40X magnification on a fluorescent microscope.  Comets were 
analyzed by KOMET software to determine the olive tail moment for ~75 images for 
each genotype and treatment. 
Results 
Shorter latency for p53 LOH in BALB/c-Trp53+/- MEFs 
 Increased loss of heterozygosity for p53 was observed in tumors from BALB/c 
Trp53+/- mice compared to their C57BL/6-Trp53+/- counterparts (Blackburn et al., 
2004b).  We were interested whether a similar increased LOH for Trp53 occurred in 
cultured cells.  Using BALB/c-Trp53+/- and C57BL/6-Trp53+/- MEFs, we determined the 
p53 genotype after each population doubling using PCR.  LOH for the remaining p53 
allele was designated for any batch of cells that showed greater than 50% signal loss of 
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the WT p53 allele.  Our results show a significantly increased amount of p53 LOH in the 
BALB/c strain compared to the C57BL/6 strains, agreeing with previous mammary tumor 
data (p=.018) (Figure 2.1).   
DNA double-strand break repair assay that distinguishes HRR from NHEJ 
 In order to address whether there are differences in DNA double-strand break 
repair between MEFs from BALB/c-Trp53+/- and C57BL/6-Trp53+/- mice, we utilized a 
plasmid dsb repair assay previously described (Akyuz et al., 2002c).  This assay had the 
advantage of having quick turnaround in the amount of data it provided.  Despite much 
effort and time, we were unable to attain consistent results using the assay (Figure 2.2).  
 We also plotted the transfection rates for each experiment with the corresponding 
HR and NHEJ rates using C57BL/6-Trp53+/- MEFs (Figure 2.3).  The plotted regression 
lines demonstrate a relationship of HR and NHEJ rates with increased transfection rates.  
BALB/c MEFs show an overall decrease in RAD51 accumulation at dsbs following 
irradiation 
 Localization of DNA repair proteins is an essential step in DNA double-strand 
break repair.  The timely delivery of repair proteins to the site as well as their clearance 
dictates how fast the repair is completed.  Much work has been done to understand the 
steps at which different proteins accumulate at the DNA double-strand break (Berkovich 
et al., 2007; Bekker-Jensen et al., 2006).  Using fluorescent antibodies, the accumulation 
of these proteins at DNA double-strand breaks was quantified following DNA damage in 
MEFs from BALB/cMed-Trp53+/- and C57BL/6-Trp53+/- mice.  We observed a robust 
time responsive curve following irradiation in both strains (Figure 2.4).  However, no 
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significant differences in the percentage of cells with two or more γ-H2AX foci were 
observed between the strains.  We chose to look at the accumulation of RAD51 to regions 
of DNA damage by measuring the percentage of cells that had co-localization of γ-H2AX 
and RAD51 in the nucleus.  While no clear differences were observed at any given time 
point, BALB/cMed-Trp53+/- MEFs had an overall significant decrease in co-localization 
of γ-H2AX and RAD51 (p<.05).  By 24 hours, the percentage of co-localization is back 
to base-line for both strains. 
The BALB/c strain does not show cell growth sensitivity to DNA damage inducing 
agents 
 The ability of cells to halt the cell cycle to repair damaged DNA before 
replication is crucial in preventing genomic instability.  Cells that have defects in DNA 
repair proteins can become sensitive to various DNA damaging agents.  A common 
method to diagnose a patient with Fanconi Anemia is to test the sensitivity of their cells 
to Mitomycin C (MMC) (Sasaki and Tonomura, 1973).  We tested the sensitivity of 
MEFs from both strains to survive in increasing concentrations of drugs causing DNA 
dsbs.  Our results clearly show dose responsive sensitivities to both camptothecin and 
MMC (Figure 2.5).  However, no differences in sensitivity to either drug were observed 
between the strains.  In addition, no sensitivity due to p53 haploinsufficiency was 
observed between the strains. 
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DNA-PKcs is not responsible for the increased DNA damage in BALB/c-Trp53+/- 
MEFs  
 The comet assay is a general DNA damage assay that has been utilized in many 
applications (Singh et al., 1988b).  Previous studies have shown that the BALB/c strain is 
sensitive to irradiation (Ponnaiya et al., 1997c; Ullrich et al., 1996b; Yu et al., 2001a).  
To demonstrate this in MEFs, we induced DNA damage by various methods and 
analyzed the amount of damage for numerous timepoints.  To confirm the validity of the 
comet assay in our hands, we first irradiated MEFs from both strains on a p53+/- 
background and analyzed the amount of damage after 5 minutes.  This time point was 
chosen so as to look at overall DNA damage before any DNA repair occurs.  Our results 
show little difference in DNA damage between the two strains using 5 Gy of irradiation 
(Figure 2.6).  Only at 20 Gy do we see significant DNA damage differences with 
BALB/c MEFs showing clear radiation sensitivity.   
 We next inquired if there was a difference in DNA repair between the two strains.  
We performed a time course experiment where we irradiated MEFs from both strains and 
fixed at various time points.  Our results show an overall increase in post-IR DNA 
damage in BALB/c-Trp53+/- MEFs (ANOVA p<.05) (Figure 2.7).  NHEJ repair is 
completed rapidly within 1-2 h whereas homologous recombination repair can take up to 
24 hours.  We chose a time point of 15 hours to properly measure the amount of 
unrepaired damage that persists after completion of NHEJ repair and may reflect 
differences in HRR efficiency.  Our results demonstrate a robust increase in IR-induced 
damage after 15 hours that was significantly higher in BALB/c MEFs compared to 
C57BL/6 MEFs (Figure 2.8).  Similar results were observed in wildtype MEFs where 
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there was also a significant difference in damaged DNA in the control groups between 
the strains.   
 Camptothecin is a topoisomerase I inhibitor that causes DNA stress and 
eventually double-strand breaks.  We tested the ability of this drug to induce DNA 
damage by adding it to the media of the cells for 15 hours before fixation.  We see similar 
results as when we induce DNA damage using irradiation with BALB/c MEFs showing 
significantly more DNA damage than C57BL/6 MEFs after 15 hours (Figure 2.9).  
Interestingly, this effect was not seen using p53 wildtype cells despite the control group 
showing significant differences.  
 While our choice of a timepoint of 15 hours most likely rules out the NHEJ 
pathway to explain DNA damage differences between the strains, we decided to address 
DNA-PKcs function directly.  We accomplished this by adding a specific inhibitor to 
DNA-PKcs function, Vanillin, to the media during the 15 hour incubation post-irradiation.  
Our results show that we see similar differences in damaged DNA between the p53+/- 
MEFs suggesting this difference is not due to DNA-PKcs function (Figure 2.10).  
Wildtype MEFs demonstrated no significant differences in the amount of DNA damage 
suggesting DNA-PKcs function may explain differences in DNA damage on a wildtype 
background.   
 The neutral comet assay is a variation that has been suggested to specifically 
select for DNA damage solely due to DNA double-strand breaks (Olive and Banath, 
1993).  We employed this method for various doses of irradiation and fixed and counted 
cells after 15 hours.  This variation appeared much less robust compared to the alkaline 
version as we only started to see an effect at 40 Gy of IR (Figure 2.11).  We also 
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measured tail length as an alternative method to quantify our results which has been 
reported when using this assay.  We see a similar trend as with olive tail moment with 
BALB/c MEFs showing significantly more damage at 40 Gy IR.     
Discussion 
 Proper repair of damaged DNA is essential for the prevention of mutagenesis and 
tumorigenesis.  Defects in proteins involved in these repair pathways can increase the risk 
of cancer incidence.  Mutations in members of the DNA double-strand break repair 
pathway are strongly linked to familial breast cancer risk (Ralhan et al., 2006).  In 
addition, it now appears that some of these proteins, such as BRCA1, have duel roles in 
both HR and NHEJ (Zhong et al., 2002).  Due to the importance of these pathways, much 
work has been done to identify new genes (Xia et al., 2006d) for which mutations may 
increase an individual’s risk for breast cancer (Tischkowitz et al., 2007). 
 Our mouse model of the BALB/c strain on a Trp53+/- background has allowed us 
to identify potential new risk alleles in breast cancer (Blackburn et al., 2003a).  The larger 
amount of p53 LOH observed in the BALB/c strain suggests defects in HRR which are 
likely related to this strain’s increased susceptibility to mammary tumors. The goal for 
this study was to show clear differences in DNA repair between the two strains that could 
explain a difference in mammary tumor latency.  
 Mouse embryonic fibroblasts (MEFs) were the model we used to address these 
questions.  These types of cells are easily isolated from the respective strains and are very 
simple to grow.  Because they are primary cells, they have a finite lifespan before 
senescing.  Before that, these cells tend to lose their remaining p53 allele within a few 
passages.  We followed MEFs from both strains for up to 10 passages and measured the 
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amount of p53 signal was present by PCR after each passage.  We were interested in how 
soon MEFs from each strain lose their remaining p53 allele as well as relate this data to 
the amount of LOH seen in tumors from both strains of mice (Blackburn et al., 2004a).  
Our results suggest that the BALB/c strain loses its p53 allele much sooner than the 
C57BL/6 strain, agreeing with observations in tumors from the strains (Figure 2.1).  
Overall, MEFs from both strains lose their remaining p53 allele within a few passages 
leading to an increased growth advantage.  This is most likely due to selection pressure, 
however, the BALB/c MEFs have also been shown to be sensitive to DNA damage from 
20% oxygen growing conditions (Parrinello et al., 2003b).  Due to the similar differences 
in LOH for p53 in both MEFs and tumors from the two strains, we conclude that MEFs 
are an appropriate model to test hypotheses concerning DNA double-strand break repair 
differences.   
 GFP reactivation assays were used to distinguish differences in the amount of 
HRR and NHEJ between the strains (Akyuz et al., 2002b).  This repair assay has the 
advantage of distinguishing between the two main pathways of DNA double-strand break 
repair by simply measuring GFP signal as an output in a very short waiting period.  
Unfortunately, we were unable to make firm conclusions using this assay.  Results day to 
day were rarely consistent despite using the same batch of cells and procedures.  
Transfection rates between different cell batches and genotypes were measured by GFP 
signal.  Transfection efficiency does not appear to be affected by MEF genotype or strain 
origin.  Percentage of GFP positive cells from proper DNA double-strand break repair 
ranged between 0.1% and 5% after correcting for transfection efficiency.  The 
transfection efficiencies also had a wide range of between 15% and 35%, leading to 
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baseline corrections that led to a large amount of statistical error.  Increases in 
transfection efficiency also seemed to correlate with increase repair (Figure 2.3).  With 
such a low percentage of positive cells, it is possible the amount of background noise 
could mask any significant differences in signals.  Using gates in the FACS software 
helped control for any background noise from dead cells, however, the possibility of 
other background noise cannot be dismissed.  The determining factor for the cell to use 
one DNA double-strand break repair pathway from another is largely dependent on which 
stage of the cell cycle it is in (Valerie and Povirk, 2003b).  Synchronizing each cell line 
might have aided in decreasing the amount of variation seen in each assay by favoring 
one repair pathway from another.  We performed our assays using baseline conditions, 
eg. no DNA damage.  It is possible that a more robust increase in repair might have been 
observed if we had irradiated the cells prior to transfection with the repair constructs.  
The downside to this is of course decreased transfection efficiency and most likely cell 
viability due to both the irradiation and transfection stresses to the cell.   
 The difficulties using the DNA repair construct assays led us to more defined and 
broader assays to measure DNA repair.  One of these assays is monitoring the 
accumulation of DNA repair proteins to sites of DNA damage by immunofluorescence.  
The advantages of this method include being able to visualize the specific repair protein 
and subsequently, certain step of DNA repair.  Accumulation of a repair protein to the 
nucleus does not necessarily implicate DNA repair.  However, the use of co-localization 
using different fluorescent anti-bodies to a repair protein and a marker for DNA damage 
allows greater specificity.  The most common marker for a DNA dsb is phosphorylation 
of the histone H2AX (Furuta et al., 2003).  Co-localization of any repair protein with γ-
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H2AX in the nucleus is thus a measure of proper accumulation and proper DNA dsb 
repair.   
 We chose to measure the amount of co-localization of RAD51 to γ-H2AX 
following DNA damage in the form of irradiation.  RAD51 is the recombinase 
responsible for strand invasion during HRR.  Cells without RAD51 have been shown to 
have large amounts of genetic instability due to deficiencies in HRR (Deans et al., 2003).  
In addition, studies have shown that mutations in H2AX lead to deficiencies in HRR due 
to improper accumulation of repair proteins like RAD51 and BRCA2 (Celeste et al., 
2002; Xie et al., 2004). We first counted the percentage of cells containing two or more 
γ-H2AX foci following irradiation.  We also counted the percentage of cells that had two 
or more foci containing co-localization of RAD51 and γ-H2AX.  Our results show a clear 
time-responsive curve of H2AX activation after 5 Gy of irradiation (Figure 2.4).  This 
suggests damage is being detected and then eventually repaired.  No difference in γ-
H2AX foci was detected between the strains.  The antibody used detects only 
phosphorylated  H2AX distinguishing inactive histone H2AX from the active version.  
However, because co-localization was not possible for γ-H2AX quantification, it is 
feasible any signal observed could be independent of DNA breaks.  This could be due to 
non-specific antibody binding that could also explain the high basal signal (~50%) 
observed in both strains.  The threshold used for quantification can also explain the high 
basal signal observed.  In addition, the basal signal observed could also be explained by 
the amount of oxygen damage primary MEFs encounter in 20% oxygen incubators 
(Parrinello et al., 2003a).   Co-localization of RAD51 with γ-H2AX showed a less robust 
curve following IR but enough of a curve to imply DNA repair.  ANOVA demonstrated a 
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significant effect of strain on co-localization of γ-H2AX and RAD51.  The BALB/c strain 
showed significantly decreased co-localization following IR suggesting either repair was 
being accomplished more quickly or that there was a defect in the accumulation of 
RAD51 to DNA double-strand breaks.  In addition, it is possible that the BALB/c strain 
was implementing a different pathway other than HRR in repair.  However, the BALB/c 
strain is previously known to be defective in the NHEJ pathway making this possibility 
unlikely (Yu et al., 2001b).  A defect in the accumulation of a repair protein suggests a 
possible defect in proper repair due to either an aberration in the protein itself or in the 
overall signaling process.   
 Cells that are defective in DNA repair are sensitive to DNA damaging drugs.  
This can be exploited in tumors defective in BRCA1 or BRCA2 by treating with a DNA 
damage inducing drug that can increase genomic instability in tumor cells while 
minimizing damage in repair efficient cells (McCabe et al., 2006).  Sensitivity to DNA 
damaging drugs is an effective test to determine if cells isolated from a patient are 
defective in a repair pathway.  Individuals suspected of having Fanconi Anemia will have 
isolated cells tested for their sensitivity to Mitomycin C (MMC) by viability.  We were 
interested if BALB/c MEFs were sensitive to DNA damaging drugs, possibly implicating 
defects in DNA repair.  We performed dose response curves using two common 
chemotherapeutics, MMC and Camptothecin. Mitomycin C (MMC) is an anti-biotic that 
inhibits DNA synthesis by covalently cross-linking complementary strands of DNA (Yun 
et al., 2005).  This stalls DNA replication by preventing the separation of the 
complementary strand.  Camptothecin is another DNA damaging agent that exerts its 
effect by indirectly causing DNA double-strand breaks.  This agent is an inhibitor of the 
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DNA unwinding enzyme topoisomerase.  Inhibition of topoisomerase can lead to 
physical stress of the DNA during replication resulting in DNA double-strand breaks.   
 We observed dose response curves from all strains using both drugs (Figure 2.5).  
No differences in drug sensitivity were observed between both strains.  Interestingly, 
neither strain with a p53 WT genotype demonstrated any sensitivity differences between 
each other as well as between MEFs with a p53+/- genotype.  These results were 
surprising due to our previous experiments establishing the BALB/c strain as having a 
defect in RAD51 localization following IR.  Any defect in DNA repair should makes 
cells sensitive to DNA damaging agents.  It is possible that the DNA repair defect may be 
so minor that it may not effect a cell’s sensitivity to a DNA damaging drug but can still 
cause genomic instability over time.  This is true for many carcinogens causing mutations 
that can increase risk for tumorigenesis.  However, the drugs used in this study cause 
replication fork dsbs by either cross-linking the DNA (MMC) or increasing DNA tension 
(Camptothecin inhibiting topoisomerase) during DNA replication.  The fact that we see a 
robust viability curve suggests the drugs are working properly.  It was also very 
interesting that the dose of p53 in the cell does not appear to effect drug sensitivity.  This 
was somewhat unexpected as p53 appears to be haploinsufficient as a tumor suppressor 
and in carcinogen-induced LOH (Venkatachalam et al., 2001).    
 Damaged DNA that is not repaired efficiently or in a timely matter have the 
potential to become mutations when the genome is replicated during mitosis.  The proper 
repair of damaged DNA is essential for the growth and continued proliferation of a cell.  
Single Cell Gel Electrophoresis (Comet Assay) is a relatively simple and sensitive assay 
to measure DNA damage at the single cell level (Singh et al., 1988a).  This assay allows 
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the user to detect the amount of unrepaired DNA damage over time by the way the DNA 
migrates through an agarose matrix.  Damaged DNA will run slower as breaks in the 
DNA lead to some unraveling and overall slower migration.  This slower migration of 
damaged DNA forms a “comet tail” behind the migrating nucleus which can then be 
measured and quantified.       
 We first investigated if there were any IR sensitivity differences between the two 
strains before DNA repair occurred.  Our results showed no significant differences in the 
amount of DNA damage after 5 minutes of 5 Gy of IR (Figure 2.6).  However, using 20 
Gy IR clearly shows that BALB/c MEFs acquire more damage than the C57BL/6 strain.  
Because these cells were fixed and processed only 5 minutes following IR, any damage 
observed is most likely not due to DNA repair differences.  This increased initial damage 
in the BALB/c strain could be explained by the effect of IR on Reactive Oxidative 
Species (ROS).  It is well established that IR will increase the amount of ROS due to the 
high energy waves disrupting members of the electron transport chain yielding increased 
free radicals (Halliwell and Gutteridge, 1984a).  These free radicals are particularly 
damaging to DNA in addition to proteins and other cellular components.  Cells that 
already have aberrations in the electron transport chain could be predisposed to increased 
IR-induced DNA damage due to the increased amount of ROS (ykin-Burns et al., 2010).  
 In order to assess the DNA repair difference, we performed a time course 
experiment after 5 Gy of IR.  We saw significantly more damage in the BALB/c strain 
(ANOVA p<.05) compared to the C57BL/6 strain (Figure 2.7).  This may reflect 
differences in NHEJ as this pathway occurs almost immediately following DNA damage 
compared to HRR which usually finishes within 24 hours.  We next chose a time point of 
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15 hours post-IR to determine if we could detect any differences in HRR between the 
strains.  Our results clearly show BALB/c MEFs having significantly more damage after 
15 hours post-IR compared to C57BL/6 MEFs (Figure 2.8).  This data suggests the 
BALB/c strain has a defect in HRR because of the increased DNA damage.  Because we 
picked 5 Gy of IR, it is unlikely the BALB/c strain has more initial damage that needs to 
be repaired due to similar amounts of damage in both strains after 5 minutes (Figure 2.6).  
In addition, choosing a 15 hour time point all but eliminates NHEJ as an explanation due 
to this pathway being completed within 2 hours post-IR.  It is still possible that any 
leftover damage not repaired by NHEJ in the BALB/c strain might have carried over to 
the 15h timepoint.   
 We were interested if this increased damage observed in the BALB/c strain was 
exclusive to IR or was similar with other DNA damaging agents.  We chose to incubate 
MEFs from both strains with the topoisomerase inhibitor Camptothecin for 15 hours.  
Our results show significantly more damage in the BALB/c strain similar to our IR 
results (Figure 2.9).  Thus, the BALB/c strain appears to be sensitive to DNA damaging 
agents.  
 The BALB/c strain is well known to be sensitive to IR due to a mutation in the 
NHEJ pathway component DNA-PKcs.  We decided to address whether this defect in 
DNA-PKcs function could explain the increased damage we observed in the BALB/c 
strain.  This was accomplished by incubating the MEFs in growth media supplemented 
with Vanillin.  Vanillin has been demonstrated to be a specific inhibitor of DNA-PKcs 
(Durant and Karran, 2003).  Thus, if this protein is responsible for the increased DNA 
damage in the BALB/c strain, incubation with Vanillin should bring levels of damage in 
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the C57BL/6 strains similar to the BALB/c strain.    Our results suggest that DNA-PKcs is 
not completely responsible for the increased damage post-IR observed in the BALB/c 
strain as inhibiting this protein does not affect the amount of damage observed at the 15 
hour timepoint (Figure 2.10).  In contrast, wildtype p53 MEFs from both strains did not 
show any significant differences in damage after treatment with Vanillin.  This was 
surprising and not easily explained.  Obviously, p53 is having an effect and perhaps 
DNA-PKcs function is inhibited in a p53+/- background.  This is not completely unforseen 
as both of these proteins have been known to interact (Woo et al., 1998).  While we 
assume Vanillin is effecting DNA-PKcs function, we could not demonstrate this directly.  
Inhibiting DNA-PKcs function by siRNA treatment in the C57BL/6 strain would be an 
appropriate alternative experiment to test this hypothesis.   
 The neutral comet assay is a variation of the comet assay that supposedly selects 
for only dsbs.  It involves running the agarose embedded cells in a neutral pH solution 
instead of an alkaline solution.  The other difference is the comets are usually quantified 
by measuring the tail length instead of the olive tail moment in the alkaline assay.  Our 
results suggest this assay is not as robust as the alkaline assay and we only see significant 
differences in damage at 40 Gy IR (Figure 2.11).  The olive tail moment quantification 
was also not very encouraging.    
 Overall, we have demonstrated differences in DNA repair between the strains 
using multiple methods.  We clearly show that the BALB/c strain has a defect in DNA 
repair due to the increased damage present over time. In addition, this increased damage 
does not appear to be specific to IR as similar differences in DNA damage were observed 
between the strains following Camptothecin treatment.  This increased damage in the 
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BALB/c strain does not appear to be due to a well known defect in the NHEJ component 
DNA-PKcs.  Immunofluorescence was used to ascertain at which step of repair is 
perturbed by showing that the BALB/c strain has a defect in the localization of RAD51 at 
dsbs following IR.   
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Figure 2.1  Differences in loss of heterozygosity in Trp53+/- MEFs from BALB/c 
and C57BL/6J mice.  Regression analysis demonstrated that slopes of the lines 
were significantly different (F-test, p=.018) 
 
 
 
 
 
 
 
 31
 Figure 2.2  DNA double-strand break repair assay. (A)  Amount of relative HRR in 
MEFs of different strains.  (B)  Same as above, except measuring amount of NHEJ in 
MEFs using an alternative construct. Percentage of GFP positive cells, indicative of 
proper repair, were counted by FACS analysis and made relative to transfection 
efficiency.  Data plotted as 3 independent experiments with an n=3 for each 
experiment. 
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Figure 2.3  Effect of transfection rate on the amount of repair using the Repair assay  (A)  
Individual experiments were plotted based on the calculated HR rate and the accompanying 
transfection efficiency using C57BL/6-Trp53+/- MEFs (B)  Same as above, except NHEJ 
rates are plotted with the accompanying transfection efficiency 
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Figure 2.4  Immunofluorescence of DNA repair proteins  (A) The percentage 
of positive cells for γ-H2AX immunofluorescence were quantified following 
2.5  Gy IR.  Values are expressed as the mean percentage of cells that have two 
or more foci ± standard error.  Each bar represents at least three independent 
experiments.  (B)  The percentage of positive cells with co-localization of 
RAD51 with γ-H2AX.  Values are expressed as the mean percentage of cells 
that have two or more foci ± standard error.  Each bar represents at least three 
independent experiments.  ANOVA *p<.05  
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 Figure 2.5  MTS assays measuring cell proliferation (A)  Camptothecin was 
added at the appropriate dose and cells were incubated for three days.  MTS 
reagent was added to each well and quantified.  Data points are plotted as mean 
absorbance units ± standard error in triplicate.  (B)  Same procedure as above, 
except MMC was added to each well for the appropriate dose.  Data points are 
plotted as mean absorbance units ± standard error in triplicate. 
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Figure 2.6  Initial IR-induced DNA damage before DNA repair.  Each bar 
represents at least three independent experiments.  Students t-test used, ***p<.001 
 
 36
Figure 2.7 Timecourse comet assay after 20 Gy of IR.  Each bar represents at least 
three independent experiments.  ANOVA used, p<.05 significance was found. 
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Figure 2.8  Amount of residual DNA damage 15 hours post-IR  (A)  MEFs 
on a p53+/- background were quantified. Each bar represents at least three 
independent experiments.  Students T-test used, ***p<.001 significance was 
found.  (B)  MEFs on a p53+/+ background were quantified. Each bar 
represents at least three independent experiments.  Students T-test used, 
***p<.001 significance was found.   
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Figure 2.9  Amount of residual DNA damage in MEFs after 15 hours incubation with 
Camptothecin 5μM (A)  MEFs on a p53+/- background were quantified. Each bar 
represents at least three independent experiments.  Students T-test used, ***p<.001 
significance was found in the treated group.  (B)  MEFs on a p53+/+ background were 
quantified. Each bar represents at least three independent experiments.  Students T-test 
used, **p<.01 significance was found in the control group.   
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 Figure 2.10  Effect of DNA-PKcs inhibitor on IR-induced dsb repair  (A)  MEFs on a p53+/-
background were quantified. Each bar represents at least three independent experiments.  
Students T-test used, **p<.01 significance was found in the control group and ***p<.001 in the 
treated group.  (B)  MEFs on a p53+/+ background were quantified. Each bar represents at least 
three independent experiments.  Students T-test used, no significance.  
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Figure 2.11  Dose response curve for Neutral Comet Assay  (A)  MEFs on a p53+/-
background were quantified by tail length. Each bar represents at least three independent 
experiments.  Students T-test used, ***p<.001 significance was found in the “40Gy” group 
(B)  MEFs on a p53+/- background were quantified by olive tail moment. Each bar represents 
at least three independent experiments.  Students T-test used, no significance.  
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CHAPTER 3 
ANALYZING THE ROLE OF PALB2 IN MAMMARY TUMOR 
SUSCEPTIBILITY IN THE BALB/C TRP53+/- STRAIN 
Introduction 
 Inheriting mutations in the most commonly known breast cancer risk alleles, 
BRCA1 and BRCA2, leads to a 80% and 60% risk of acquiring the disease in an 
individual’s lifetime (Narod, 2002).  While BRCA1 appears to have many functions in 
the cell, BRCA2 appears to be primarily involved in the DNA double-strand break repair 
pathway (Abaji et al., 2005).  This suggests the DNA double-strand break repair pathway 
as being an essential component of the cell to prevent genomic instability and thus 
tumorigenesis.  BRCA2 has been shown to work as a complex with a number of other 
proteins to perform dsb repair.  One member was identified bound to a complex of 
BRCA2 and a number of other proteins previously identified (Xia et al., 2006c).  This 
particular member was subsequently named Partner and localizer of BRCA2 (PALB2).  It 
was demonstrated that PALB2 is necessary for BRCA2 to localize to DNA double-strand 
breaks and that when PALB2 is knocked down by siRNA, HRR function is diminished.  
PALB2 appears to bind to D-loop DNA and help stimulate strand invasion through 
RAD51 (Buisson et al., 2010).   Complete loss of PALB2 was shown to result in a new 
subtype (N) of Fanconi Anemia (FA) in an individual (Xia et al., 2007b).  Cells from this 
patient showed sensitivity to DNA cross-linkers such as MMC that is a hallmark of FA 
cells.   
 PALB2 is an 1,186 amino acid protein that has an N-terminal coiled-coil region 
and C-terminal WD-repeats (Xia et al., 2006b).  The C-terminal region was later 
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identified as where the extreme N-terminal region of BRCA2 binds to (Oliver et al., 
2009).   PALB2 has been shown by multiple studies that to bind both BRCA1 and 
BRCA2 in a complex by way of its N-terminal domain binding BRCA1 and its C-
terminal domain binding BRCA2 (Zhang et al., 2009b; Zhang et al., 2009a; Sy et al., 
2009).   Mutations in this region abrogate the binding of PALB2 to BRCA2 and lead to 
diminished HRR function.  Interestingly, there were 3 mutations in the N-terminal region 
of BRCA2 from breast cancer patients that disrupted PALB2 to binding highlighting the 
significance of this gene.  Recent work has identified a number of mutations and 
truncations in PALB2 in breast cancer families.  An initial study identified 10 familial 
breast cancer patients that had monoallelic truncating PALB2 mutations (Rahman et al., 
2007a).  These mutations conferred a 2.3-fold increased risk of breast cancer.  A 
frameshift mutation, 1592delT, was seen at a higher frequency in Finnish breast cancer 
patients compared to the control population (Erkko et al., 2007).  Numerous other studies 
have identified other mutations of PALB2 in breast cancer patients (Tischkowitz and Xia, 
2010).  All of these studies demonstrate the importance of PALB2 in complex with 
BRCA1 and BRCA2 in performing HRR.  Individuals with mutations in any one of these 
genes can have an increased risk of genomic instability and breast cancer.   
 The Palb2 gene in the mouse is located at 129.25 Mb on chromosome 7 
(ensemble v.60).  This location is almost directly under the prominent second peak in the 
mapped SuprMam1 region.  With its clear role in DNA double-strand break repair and 
being a breast cancer risk allele, this gene was chosen as an obvious candidate to explain 
spontaneous mammary tumor differences between C57BL/6 and BALB/c mice on a 
p53+/- background.  In addition, our work demonstrating decreased RAD51 localization to 
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DNA double-strand breaks in the BALB/c strain implicates PALB2 by its association to 
RAD51 in a complex with BRCA1 and BRCA2 (Figure 1.2).  To explore this, we sought 
to examine expression differences of this gene in the mammary gland of both strains.  In 
addition, we also attempted to identify sequence differences in the form of SNPs between 
the two strains.  This was accomplished in two ways.  First, we searched for SNPs using 
an online database.  Next, we sequenced the entire coding region of Palb2 between the 
two strains of mice.  Finally, we generated an expression vector of Palb2, with and 
without a GFP and IRES section. 
Methods 
QPCR expression of Palb2:   
The fourth mammary gland was removed from mice 8-10 weeks of age and stored at -
80oC.  Total RNA was isolated using Trizol solution according to protocol.  Isolated 
RNA  was reverse transcribed using Stratagene AffinityScript cDNA kit  and analyzed 
for gene expression using Stratagene Brilliant II SYBR Green kit.  Three animals were 
used for each strain and normalized to Actin expression.  Primers for Palb2 expression 
were 5’-GACCTGCTGGAAAGGCCACCAC-3’ for the forward primer and 5’-
CAGTTTTTCCGAGCAGGACTTCAAT-3’ for the reverse primer.  Actin primers were 
5’-CTAAGGCCAACCGTGAAAAG-3’ for the forward primer and 5’-
ACCAGAGGCATACAGGGACA-3’ for the reverse primer.  Fold change was 
established by dividing mean BALB/c expression to mean C57BL/6 expression.  
Statistical significance was determined by using Student’s T-test. 
Generation of primary mammary epithelial cells: 
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Primary mammary epithelial cells were dissociated from isolate mammary glands using 
the protocol associated with the product EpiCult-B medium (Stemcell Technologies).  
Briefly, the fourth mammary gland was removed from mice 8-10 weeks of age and 
minced using a razor blade.  The minced tissue was then incubated with a digestion 
medium containing collagenase type 3 (Worthington), hyaluronidase (Sigma), FBS 
(Gibco) and antibiotics for 1-3 hours.  The tissue was then spun down by centrifugation 
and washed multiple times with Hanks buffered solution (Gibco) containing 2% FBS.  
After being pelleted, the tissue mixture was then resuspended in trypsin-EDTA for 1-2 
min., followed by a wash of Hanks buffered solution with FBS.  Following 
centrifugation, the pellet was resuspended in 5mg/ml of Dispase (Gibco) for 1 minute 
before being washed by Hanks buffered solution and pelleted by centrifugation.  The 
pellet was resuspended in Complete Epicult-B Medium supplemented with 10 ng/mL 
mouse Epidermal Growth Factor (mEGF) (Sigma), 10 ng/mL recombinant human 
Fibroblast Growth Factor (rh bFGF) (Stemcell Technologies), 5% FBS (Gibco), 4 μg/mL 
Heparin (Stemcell Technologies), 1X Pen/Strep (Gibco)  and Gentamycin (Gibco) and 
plated in a 6-well plate.  Two days later, medium with floating cells and debris was 
removed and any plated cells were incubated with EpiCult-B medium without FBS.  
Cells continued to grow in this media until wells were 70% confluent at which point 
RNA was isolated. 
SNP identification: 
The database located at http://www.genenetwork.org/webqtl/snpBrowser.py was used to 
identify any SNP differences in Palb2 between the C57BL/6 and BALB/c strains. 
Palb2 mRNA sequencing: 
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RNA was isolated from the fourth inguinal mammary gland of BALB/c and C57BL/6 
mice using Trizol.  Reverse transcription was performed by Stratagene’s cDNA synthesis 
kit (Stratagene).  Because the coding region of Palb2 is 3747 bp, we decided to amplify 
this region in two sections.  The first section was amplified using the forward primer 5’-
AACCTGTGTGGCTCGGCAGGAACATAGT-3’ and the reverse primer 5’-
CCAGTGTGGAGGTGCGGGCTGATT-3’.  The second section was amplified by using 
the primers 5’- TGCAGAATACTATGTTAGAACAACCCGTCGTAT-3’ and 5’-
GTCACAAGCAGGGCGATCTGCAGTTTC-3’.  After each subsequent PCR, the 
amplified product was subcloned into a blunt end pCR-Blunt-II-TOPO vector 
(Invitrogen) and transformed into E.coli GC-10 competent bacteria.  After confirmation 
for colonies with the appropriate vector insertion, the plasmids were sent out for 
sequencing.  Palb2 was sequenced using two primers that bound to the TOPO vector (T7 
and M13R) and flanked the coding region.  In addition, an internal primer was used (5’-
CTTCATCCATAGTGCTTTTC-3’) to sequence toward the 3’ end.  Analysis of the 
sequencing data was performed by using Vector NTI (Invitrogen) software.    
Construction of a Palb2 expression vector: 
RNA was isolated from the fourth inguinal mammary gland of BALB/c and C57BL/6 
mice using Trizol.  Reverse transcription was performed by Stratagene’s cDNA synthesis 
kit (Stratagene).  Palb2 coding sequence was amplified using two primers (5’-
AACCTGTGTGGCTCGGCAGGAACATAGT-3’ and 5’-
TCACTGGTTATGTACAGCTGTAATAGCAAATGTGC-3’) before being cloned into a 
TOPO vector and transformed into TOP10 cells.  After confirmation of appropriate 
insertion by restriction enzyme cutting and DNA sequencing, the Palb2 insert was cut out 
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using the endonucleases SpeI and NotI.  The SpeI end of the Palb2 insertion was then  
blunt ended by T4 polymerase (Roche) and ligated into the EcoRV and NotI sites of the 
pIRES-hrGFP II construct.  The GFP-IRES (4262-5920 bp) portion of the pIRES-GFP-
Palb2 plasmid was removed by cutting the construct with XbaI and NotI.  The cut sites 
for the construct minus the GFP-IRES portion (Stratagene) was then filled in for blunt-
end ligation by T4 polymaerase (New England BioLabs).  Gel purification was then 
performed and the construct minus the GFP-IRES portion was ligated together and 
transformed into GC10 cells.  Restriction enzyme cutting and DNA sequencing was used 
to screen for positive clones that contained the pIRES-ΔGFP-ΔIRES-Palb construct.      
Results 
No difference in Palb2 expression observed in the mammary gland between both 
strains 
 Sequencing of genomes of different mouse strains has produced a wealth of data 
available in the public domain.  Using a SNP database developed by members at the 
University of Tennessee, we examined SNPs within the promoter and transcribed region 
of Palb2.  One polymorphic intronic SNP for Palb2 was identified (Figure 3.2).  This 
SNP was located in intron 7 of Palb2 which is unlikely to affect the protein’s function but 
could alter levels of mRNA.  No differing SNPs were identified in the promoter region of 
Palb2 between the strains.  
Palb2 expression was measured by RT-QPCR in the mammary glands of both 
BALB/c and C57BL/6J strains (Figure 3.1).  No difference in expression was observed 
for Palb2 between the strains using RNA isolated from whole mammary glands.  Because 
Palb2 is involved in the DNA double-strand break repair pathway, stimulation of the 
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DNA damage response may increase the expression of this gene.  Thus, RNA was 
isolated from mammary glands from both strains 6h following 5 Gy of IR.  No difference 
in Palb2 expression was seen in mammary glands from both strains post DNA damage 
stimulation.  Epithelial cells make up approximately 30% of the mass of the mammary 
gland.  Thus, any signals from these cells may be masked by signals from the 
surrounding stroma and adipose tissue.   Primary mammary epithelial cells were isolated 
from mammary glands of both strains.  At approximately 70% confluency, RNA was 
isolated.  No difference in Palb2 was seen in primary mammary epithelial cells from 
these strains.  
No sequence differences in Palb2 mRNA was observed between the strains 
 Despite the amount of information available in the public domain, not all of this 
data is complete.  Sequence variations can sometimes be difficult to detect in large-scale 
sequencing projects due to the overwhelming amount of data and inherent error that 
accompanies these studies.  Insertions and deletions are especially under-represented. 
With this in mind, the entire protein coding region of the  Palb2 mRNA was cloned and 
sequenced for both strains.  We used primers for sequencing that overlapped allowing 
redundant sequencing for any given nucleotide and demonstrated that the sequences were 
identical for both strains (Figure 3.3).   
Creating an expression vector for Palb2 
 Little work has been done identifying the function and expression of Palb2 in 
mice compared to humans (Xia et al., 2006a).  To help in the production of these 
experiments, we proceeded to clone Palb2 into an expression vector under the control of 
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a CMV promoter (Figure 3.4).  The construct also has an IRES site and GFP signal.  
Another construct was made exactly the same but minus the IRES and GFP for use in Dr. 
Lisa Wiesmüller’s DNA repair assays (Figure 3.5) (Akyuz et al., 2002a).  Transfection 
of the vector into MEFs increased the reactivation of GFP-reporters in C57BL/6J MEFs 
(personal communication, L. Wiesmüller). 
Discussion 
 The amount of familial breast cancer cases due to inherited mutations in genes 
involved in DNA repair highlights this pathway as critical in the prevention of breast 
tumorigenesis.  Much work has been done over the years to identify new potential breast 
cancer risk alleles since the most common high penetrant alleles only make up of 
approximately 20% familial risk (Ponder, 2001a).   
 Palb2 was chosen as a viable candidate to explain spontaneous mammary tumors 
in the BALB/c strand for a number reasons.  First, the gene for Palb2 in mouse was 
localized directly under the second prominent peak in the SuprMam1 interval.  Second, 
Palb2 is considered a low penetrance modifier due to confering a 2.3 fold risk for breast 
cancer which is precisely the relative risk associated with the SuprMam1 region in the 
BALB/c strain.  
 We were interested to determine if there were any SNP differences for Palb2 
between the strains.  Using a public domain database, we identified one SNP between the 
two strains.  Unfortunately, this SNP is localized in the intron of the gene where it is most 
likely not affecting the protein.  This intron is unlikely to affect splicing as it is localized 
too far away from the exon-intron borders.  In addition, the database takes into account 
SNPs that are possible splice site variants.   
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 To verify the results from the database, we proceeded to sequence the coding 
region of Palb2 using RNA isolated from mammary glands of both strains.  Using a 
strategy of overlapping sequencing results, we did not identify any sequence differences 
between the strains.   
 We also looked at expression of this gene in whole mammary gland, irradiated 
mammary gland and primary mammary epithelial cells.  We did not observe a significant 
difference in expression of this gene between the strains in any of the three sources.  This 
includes primary mammary epithelial cells which were used in case any signal was 
masked by stromal or adipose cells in the whole mammary gland.  Because Palb2 is 
active in the DNA damage response, we supposed that irradiating the mammary gland 
might boost the expression of this gene.  Though unlikely, it is possible that there are 
differences in Palb2 expression between the strains that are too subtle to be detected by 
QPCR alone.   
  These results suggest there are no differences in Palb2 expression or 
protein function between the strains.  However, this does not fully rule out Palb2 as a 
candidate gene.  We had thought about assaying PALB2 function by observing BRCA2 
localization to DNA double-strand breaks following DNA damage (Xia et al., 2006e).  
However, antibodies for mouse BRCA2 are very unreliable and immunofluorescence for 
BRCA2 requires very robust antibodies.  It is also possible an element within the 
SuprMam1 region may be affecting Palb2 function post-translationally.  In fact, using 
simple protein modeling software (Figure 3.6), we identified Polo-like Kinase 1 (Plk1) as 
a potential binding partner of Palb2.  Plk1, like Palb2, is localized within the SuprMam1 
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region, where it could be modifying PALB2 function post-translationally.  Therefore, 
further assays of PALB2 activity are needed.         
 Searching for additional DNA repair genes within the SuprMam1 interval resulted 
in no other candidates besides Palb2.  This suggests genes in other pathways besides 
DNA repair may be responsible for increased tumor latency in the BALB/c strain.  It is 
possible there are genes within this interval with undefined roles in DNA repair yet to be 
identified.  Since Palb2 was one of these genes prior to the 2006 study, this remains a 
reasonable possibility.   
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Figure 3.1  Palb2 expression from whole mammary gland RNA is shown relative 
to C57BL/6 expression and normalized to Actin expression.  Expression of Palb2 is 
also shown for mammary glands 6 hours post-IR 5 Gy.  Finally, expression of 
Palb2 was ascertained from primary epithelial cells from both strains of mice.  No 
significant expression differences were observed.   
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Figure 3.2  Diagram of the mouse Palb2 gene showing the location of the one 
SNP identified that differs between the strains (G=C57BL/6, A=BALB/c).  No 
SNP differences were observed between the strains in the Palb2 promoter 
region. 
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Figure 3.3  Sequencing strategy for Palb2 coding region.  Due to the length of the 
mRNA, two separate sections were amplified using RNA isolated from the mammary 
glands of both strains.  The above cloning primers were used in an RT-PCR reaction 
and the subsequent amplicons were subcloned into a pCR TOPO vector.  Sequencing 
was done using the above primers and Vector NTI software was used to visualize the 
sequencing results.   
Long-5: 
5’ AACCTGTGTGGCTCGGCAGGAACATAGT 3’
‘1671’:
5’ CCAGTGTGGAGGTGCGGGCTGATT 3’
Mid5:
5’ TGCAGAATACTATGTTAGAACAACCCGTCGTAT 3’
Long-3:
5’ TCACTGGTTATGTACAGCTGTAATAGCAAATGTCG3’
Long-5 Mid-5
‘1671’ Long-3
Palb2 ORF
1645 bp
2389 bp
26bp 1671 bp
1331 bp 3720 bp
PCR pieces cloned into pCR TOPO plasmids and sent for sequencing
Cloning Primers Sequencing Primers
M-13: 
5’ TAATACGACTCACTATAGGG3’
T7: 
5’ CAGGAAACAGCTATGAC 3’
179 bp translation start site 3492 bp translation stop site
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pIRES-GFP-Palb2 v.2
9256 bp
TOPO binding site
TOPO binding site
BamHI (729)
ClaI (7126)
Sma I (706)
XmaI (704)
Asc I (3)
BglII (750)
BsaBI (7145)
MfeI (4099)
MluI (30)
NdeI (286)
NotI (4493)
Pme I (769)
Sac II (1651)
SfiI (7061)
SnaBI (392)
Spe I (51)
SrfI (706)
ApaLI (5084)
ApaLI (8890)
DraIII (4970)
DraIII (6423)
EagI (4493)
EagI (7192) KpnI (721)
KpnI (5052)
Nhe I (998)
NheI (4205)
PmlI (4923)
PmlI (5271)
Sbf I (764)
Sbf I (5222)
Ssp I (6215)
Ssp I (6768)
XhoI (3177)
XhoI (5906)
BsaXI (927)BsaXI (6387)
CMV promoter
CMV Promoter:  1-665 bp
Forward sequencing primer binding site
[5’ ATGGGCGGTAGGCGTGTA 3’] : 576-593
T7 primer binding site
[5’ TAATACGACTCACTATAGGG 3’] : 665-684
Palb2 mRNA: 785-4478 
3X FLAG tag: 4519-4590
Reverse sequencing primer binding site
[5’ ATGCAGTCGTCGAGGAATTG 3’] : 4597- 4616
IRES site:  4626-5200
hrGFP ORF:  5204-5920
T3 primer binding site
[5’ AATTAACCCTCACTAAAGGG 3’] : 5953-5972
Bovine growth hormone (BGH) polyA signal: 5974-6204
F1 origin of ss-DNA replication: 6221-6505
Bla promoter: 6541-6665
SV40 promoter: 6685-7002
Neomycin/kanamycin resistance ORF: 7037-7486
HSV-thymidine kinase (TK) polyA signal: 7487-7936
pUC origin of replication: 8074-8741
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IRES
hrGFP
pUC origin of replication
Neo/Kan 
polyA
Figure 3.4  Plasmid map of pIRES-GFP-Palb2, an expression vector for Palb2.   
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pIRES-deltaGFP-deltaIRES-Palb2
7835 bp
TOPO binding site
TOPO binding site
ApaLI (7469)
BamHI (729)ClaI (5705)
Sma I (706)
XmaI (704)
Asc I (3)
BglII (750)
BsaBI (5724)
DraIII (5002)
EagI (5771)
KpnI (721)
MfeI (4099)
MluI (30)
NdeI (286)
Pme I (769)
Sac II (1651)
Sbf I (764)
SfiI (5640)
SnaBI (392)
Spe I (51)
SrfI (706)
Xho I (3177)
CMV Promoter:  1-665 bp
Forward sequencing primer binding site
[5’ ATGGGCGGTAGGCGTGTA 3’] : 576-593
T7 primer binding site
[5’ TAATACGACTCACTATAGGG 3’] : 665-684
Palb2 mRNA: 785-4478 
T3 primer binding site
[5’ AATTAACCCTCACTAAAGGG 3’] : 4532-4551
Bovine growth hormone (BGH) polyA signal: 4553-4783
F1 origin of ss-DNA replication: 4800-5084
Bla promoter: 5121-5245
SV40 promoter: 5265-5582
Neomycin/kanamycin resistance ORF: 5617-6066
HSV-thymidine kinase (TK) polyA signal: 6067-6516
pUC origin of replication: 6654-7321
AflIII (30)
AflIII (7783)
HindIII (691)
NarI (5865)
HindIII (1114)
AarI (1278)
AarI (2879)
ApaI (1752)
ApaI (4507)
KasI (4763)
KasI (5864)
NarI (4764)
Nhe I (998)
Nhe I (4205) PspOMI (1748)
PspOMI (4503)
SapI (937)
SapI (3545)
Ssp I (4794)
Ssp I (5347)
XmnI (1972)
XmnI (2077)
BsaXI (927)
BsaXI (4966) Neo/Kan 
pUC origin of replication
CMV promoter
polyA
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Figure 3.5  Plasmid map for pIRES-deltaGPP-deltaIRES-Palb2, an expression vector for 
Palb2.  The region of the plasmid containing the IRES and hrGFP features were removed 
and the resulting linear plasmid was re-ligated.   
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Figure 3.6  Mouse PALB2 protein modeling using PVS protein modeling software 
(http://imed.med.ucm.es/PVS/).  “LIG” designates proteins that theoretically bind to 
PALB2 while “MOD” designates proteins that modify PALB2.  Polo-like kinase 1 (PLK) 
is fifth from the bottom. 
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 CHAPTER 4 
IDENTFICATION OF GENES WITHIN THE SUPRMAM1 INTERVAL THAT 
CONTRIBUTE TO INCREASED MAMMARY SUSCEPTIBILITY IN THE 
BALB/C STRAIN 
Introduction 
 The search for high penetrance genetic modifiers for breast cancer using linkage 
approaches has been successful and has led to the identification of BRCA1, BRCA2 and 
TP53 which make up 20% of the familial breast cancer risk (Antoniou and Easton, 2006).  
However, this leaves genes contributing to 80% of familial risk of breast cancer 
unaccounted for.   
 Genome wide association studies have been relatively successful in identifying 
low penetrance modifiers to breast cancer.  However, the disadvantages of requiring 
thousands of patients and controls makes these studies difficult to reproduce.  The use of 
inbred mice provides the necessary tools to identify low penetrance alleles.  Specifically, 
the BALB/c strain has proven to be useful to due its propensity for mammary tumors 
(Heston and Vlahakis, 1971).  On a p53+/- background, this increased mammary tumor 
frequency becomes even more apparent.  BALB/cMed Trp53+/- have spontaneous 
mammary tumor incidence rates between 42% and 65% (Kuperwasser et al., 2000b; 
Blackburn et al., 2003b).  In contrast, the C57BL/6 develops mammary tumors less than 
1% of the time (Donehower et al., 1992; Jacks et al., 1994).  These two strains are useful 
models in identifying potential new low penetrance modifiers to breast cancer. 
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 Previous work from our lab identified a region on chromosome 7 that linked to 
decreased mammary tumor latency in the BALB/c Trp53+/- strain (Blackburn et al., 
2007d).  Based on microarray data and the mapping data, Dmbt1 was chosen as a suitable 
candidate.  However, higher resolution mapping is needed to refine the localization of 
candidates.  
 In order to identify new candidates to explain the observed genetic linkage, we 
analyzed new markers within the SuprMam1 region with the intention to provide better 
mapping resolution.  We also employed a strategy to narrow down the list of candidates 
by selecting for genes that have coding SNP differences between the strains.  Finally, we 
looked at gene expression by QPCR of our list of candidates between the strains.     
Methods 
Real-time RT-PCR:   
The fourth mammary gland was removed from mice 8-10 weeks of age and placed at -
80oC.  Total RNA was isolated using Trizol solution according to protocol.  Isolated 
RNA  was reverse transcribed using Stratagene cDNA kit  and analyzed for gene 
expression using Stratagene Brilliant-II-SYBR Green kit.  Three animals were used for 
each strain and normalized to Actin expression.  Fold change was established by dividing 
mean BALB/c expression to mean C57BL/6 expression.  Statistical significance was 
determined by using Student’s T-test. 
Defining the SuprMam1 region: 
An additional 8 SNPs were selected based on the ability of the SNP to disrupt a 
restriction enzyme cut site (Table 4.1b).   Flanking primers to the SNP were used to 
generate an amplicon by PCR which was then cut with the appropriate restriction enzyme 
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(Table 4.1a).  The genotype for each marker in an animal was determined by the size of 
the cut or uncut amplicon by electrophoresis.  LOD scores were determined by Chi-
squared tests for each marker.  
Selection of Candidate Genes: 
The total list of genes within the SuprMAM1 interval was generated by using the 
Ensembl database (http://www.ensembl.org/index.html) version 59.    Using the Jackson 
Labs SNP database (http://phenome.jax.org/), the total list of genes within the SuprMam1 
interval was filtered down to only include non-synonymous  SNPs that were contained 
within exons, untranslated regions as well as potential splice sites.  SNP density maps 
were also generated using the Jackson Labs SNP database.  Genes that showed significant 
differences in expression (p<.05) between the respective strains by microarray(Blackburn 
et al., 2007c) were also included. 
Results 
Narrowing of the SuprMam1 interval 
 There are 199 genes within the 15 Mb of the defined SuprMam1 region from 120-
135 Mb.  In order to narrow down the list of candidate genes, eight more SNP markers 
were chosen within this region to achieve greater resolution.   Use of these markers led to 
the narrowing of the interval from 100 Mb-135 Mb  to 120-135 Mb total.  Two distinct 
peaks correspond to the SNP marker Plekha7 and the markers Jmjd5, Il21r and Rabep, 
respectively.  Analysis for genes within the SuprMam1 interval that had SNP differences 
between the susceptible BALB/c strain and three resistant to mammary tumors strains 
(C57BL/6, DBA/2J and 129SvJ) identified two distinct quantitative trait loci (QTLs) 
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termed SM1a and SM1b.  These QTLs were localized directly under the peaks identified 
within the SuprMam1 region.       
Candidate genes within the SuprMam1 interval 
 A criterion was used to narrow the total genes within the SuprMam1 region.  
Using this filtering revealed a total of 34 genes that grouped into two apparent haplotype 
blocks, one that spanned from 122.6 Mb to 127.35 Mb and the other from 132.6 Mb to 
134.5 Mb (Table 4.2).  Primers were designed for 32 of these genes using the Roche 
primer design database.  Only 17 primer sets were able to demonstrate clear expression of 
the respective genes in the mammary gland.  Eleven of the remaining primers that did not 
work were used to amplify MEF RNA to confirm that these genes were not expressed in 
the mammary gland (Table 4.3).  QPCR was used to examine expression differences 
within the mammary glands of the respective strains.  No significant expression 
differences were observed in 17 of the candidate genes tested (Figure 4.2).  Similarly, no 
expression differences were observed in mammary glands that had been irradiated in vivo 
from the two strains (Figure 4.3).  Expression of stromal and adipose tissue can mask 
signals from the epithelium.  We observe a significant increase in IL21r in the BALB/c 
strain in primary mammary epithelial cells (Figure 4.4).  When we compared C57BL/6 
expression with BALB.B6-SuprMam1 mammary epithelial cell expression, we observed 
significant differences in three genes, Tmem159, Il21r and Itgal (Figure 4.5).  Tmem159 
was significantly decreased in the congenic strain while Il21r and Itgal were found to be 
significantly increased in expression.  
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Discussion 
 In this study, we have attempted to utilize our model for spontaneous mammary 
tumor incidence to identify potential new low penetrance modifiers.  The initial map for 
SuprMam1 published by our group spanned approximately 30Mb on chromosome 7 and 
contained approximately 200 genes.  It contained two subtle peaks that may correspond 
to more than one gene in our interval.  Using eight additional markers within the 
SuprMam1 interval, we were able to achieve greater resolution.  The peaks revealing 
more prominent peaks with more defined boundaries. The result suggests that at least 2 
genes within the SuprMam1 region contribute to the mammary tumor phenotypes in the 
Trp53+/- mice.  
 Attempting to analyze 199 genes was a daunting task, so a filtering strategy was 
devised to narrow this list down.  Utilizing the criteria in Figure 4.1, we filtered the initial 
199 genes to 27 total which grouped into two distinct haplotype blocks, SM1a and SM1b.  
Grouping these two haplotype blocks on our map placed them almost directly under the 
two prominent peaks of SuprMam1.  In addition, we included another 7 genes based on 
significant expression differences from a microarray comparing gene expression 
signatures between our two strains (Blackburn et al., 2007b).        
     A SNP database was used to identify regions of SNP density differences 
between different strains of mice.  The DBA and 129/Sv strains are resistant to mammary 
tumors similar to the C57BL/6 mice (Backlund et al., 2001b; Ghebranious and 
Donehower, 1998).  Thus, we searched for SNP density differences in the SuprMam1 
region between the susceptible strain BALB/c and the three common resistant strains.  
We then proceeded to determine where the two haplotype blocks SM1a and SM1b 
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corresponded to the SNP densities.  Interestingly, both blocks were localized to regions 
of high SNP difference densities.  In particular, SM1b was localized to a previously 
identified haploblock, IL4PPQ.  This region was identified in a genetic linkage study for 
lupus and corresponds to the gene Il4r in addition to a few other genes (Shiroiwa et al., 
2007).  The Il4r pathway has been shown to contribute to apoptosis resistance in 
epithelial cancer cells (Todaro et al., 2008).  We did not detect any expression differences 
in the Il4r between the strains but did detect non-synonymous SNP differences (Table 2, 
as a candidate gene).  There are clear immune response differences between these two 
strains as the BALB/c strain has a T helper cell type 2 (TH2)  response to immune system 
stimulation while the C57BL/6 strains is more TH1(Liu et al., 2002).  This is evident in 
the BALB/c strains susceptibility to intracellular parasite infection, resistance to 
autoimmune disease and overall increased cancer incidence compared to the C57BL/6 
strain.  How relevant the IL4PPQ and/or Il4r is to mammary susceptibility is unknown, 
but it is tempting to speculate that a common gene may explain increased susceptibilities 
to both phenotypes.   
 We proceeded to examine gene expression of our candidate genes in RNA 
isolated from whole mammary glands.  Unfortunately, no significant expression 
differences were detected.  Similarly, no expression differences were detected in RNA 
isolated from mammary glands following irradiation.  Because the mammary epithelium 
only makes up 30% of total tissue within the breast, any signals from the stroma or 
adipose cells could mask epithelial signals.  Using RNA from primary mammary 
epithelial cells, our QPCR results show a significant increase in the Il21r in the BALB/c 
strain.  Analyzing expression of genes from the congenic strain allows us to eliminate 
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genes being activated by promoter elements contained outside the SuprMam1 region.  
Our QPCR results from BALB.B6-SuprMam1 mammary epithelial cells show significant 
increases in expression of Il21r and Itgal in contrast to a decreased Tmem159 expression.  
The increased Il21r expression present in both the BALB/c and BALB.B6-SuprMam1 
strains suggest that despite this gene being contained within the SuprMam1 region, its 
expression is being controlled by an element outside the interval.  The increased 
expression of Itgal and decreased expression of Tmem159 in the congenic strain is a little 
more difficult to explain.  No expression differences were observed in BALB/c cells with 
these two genes suggesting a possible disruption of signaling with BALB/c elements 
outside the interval and C57BL/6 elements within the interval.  Normalizing to Actin was 
necessary for this data as this gene was found to be differentially expressed between the 
congenic and C57BL/6 strains.  While care is taken to be certain the same amounts of 
input RNA are added for cDNA synthesis, it is possible there were user or technical 
errors in this case.     
 The lack of significant gene expression differences between the two strains was 
disappointing.  It is possible that our method of narrowing the list of candidates was too 
stringent and excluded other candidates.  We were also unable to confirm any of the 
seven genes identified in the microarray by QPCR.  While we were able to identify a list 
of candidates with a non-synomymous SNP difference between the strains, we did not 
have the resources or tools to test the functionality of these SNPs on protein function.  
There is a third possibility in which non-coding regions within SuprMam1 encode 
miRNAs.  This is not beyond the realm of possibilities as many of the SNPs identified in 
genome wide association studies were located in non-coding regions (Easton et al., 
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2007c).  It is also possible that there is a gene exerting its effect on mammary latency 
through a host effect.  This was apparent in a study by Veillet et al where they identified 
a gene whose differential expression in the thymus was exerting its effect on mammary 
carcinogenesis (Veillet et al., 2011).  Future studies will need to be done to follow up 
these possibilities.  
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 Figure 4.1  Revised SuprMam1 interval with 8 additional markers.  Flow chart describes 
the candidate gene filtering process.  Candidates grouped into two distinctive 
haploblocks that mapped directly under the prominent peaks.  Below the mapped 
haploblocks are the SNP densities for (Top to bottom): BALB/c (yellow background), 
C57BL/6, DBA and 129Sv strains.   
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 Figure 4.2  Candidate gene expression from whole mammary glands.  (A)  Expression of 
BALB/c Trp53+/- mammary glands Log2 change to C57BL/6 Trp53+/- mammary glands.  
Mammary glands were IR at 5 Gy and harvested 6 hours later.  At least three mice were used per 
group, error bars represent standard error.  No significant differences observed by ANOVA.  (B)  
Same as above, but not normalized to Actin.    
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Figure 4.3  Candidate gene expression from IR mammary glands  (A)  Expression of BALB/c 
Trp53+/- IR mammary glands Log2 change to C57BL/6 Trp53+/- IR mammary glands.   At least 
three mice were used per group, error bars represent standard error.  No significance by ANOVA.  
(B)  Same as above, but not normalized to Actin. 
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Figure 4.4  Candidate gene expression from BALB/c Trp53+/- primary mammary 
epithelial cells.  (A)  Expression of BALB/c Trp53+/- epithelial cells Log2 change to 
C57BL/6 Trp53+/- epithelial cells.   At least three mice were used per group, error bars 
represent standard error.  Significance by ANOVA, *p<.05.  (B)  Same as above, but not 
normalized for Actin 
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 Figure 4.5  Candidate gene expression from BALB.B6-SuprMam1 Trp53+/- primary 
mammary epithelial cells.  (A)  Expression of BALB.B6-SuprMam1 Trp53+/- epithelial 
cells Log2 change to C57BL/6 Trp53+/- epithelial cells.   At least three mice were used per 
group, error bars represent standard error.  Significance by ANOVA, *p<.05, **p<.01.  
(B)  Same as above, but not normalized for β-actin.  Significance by ANOVA, *p<.05, 
**p<.01, ***p<.001 
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A Gene forward reverse 
Plekha7 GTCATTTACACCTTGTTAGTCTGTG
TC 
CCTTTCAGCCTCTCTTCTGTGGTA 
Tmc5 GCCCTCTCAGGCTTATCCTCCA GGGACAGCCCTGTTTGAGTTCC 
Abca14 CACGTTGATGTGGCAACTTGGAC TCACCTGAAGTGGCAAGCGTTC 
Jmjd5 CCACTAACGCAGATTCCTGACAC CCTGGGGACACTCACTGG 
Rabep2 GGTAGGTACTATCCCTGCCAGCA GTTGAACTCACCTGCTTGGCAC 
Dock1 CAGGGGCAAGGAGAAGAAGGAA GCAGGTGGCTGATGGTTCTGAG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B Gene Mb b6/bal
b 
Enzyme Cuts Bk6 Amplicon Balb/c 
Amplicon 
Plekha7 115.966915 A/G BsaxI Balb/C 374bp 202bp 172bp 
Tmc5 118.443806 A/G MboI Balb/C 466bp 268bp 178bp 
Abca14 120.042328 C/T HhaI C57/BK6 97bp 72bp 169bp 
Jmjd5 125.246382 C/T BsrI C57/BK6 203bp 65bp 58bp 261bp 65bp 
Rabep2 126.231357 G/A BsrbI C57/BK6 97bp 67bp 164bp 
Dock1 134.627560 G/C PvuII C57/BK6 296bp 209bp 505bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 4.1  Primers and SNPs used for SuprMam1 genotyping.  (A)  Primers used to 
amplify amplicon containing the SNP in the appropriate gene.   (B)  Table showing the 
SNP associated gene, its location and the SNP for each strain.  In addition, the enzyme 
next to each SNP indicates the restriction enzyme cut site used to genotype each N2 
mouse at that particular genomic location.   
 
 
 
 
 71
 Table 4.2  List of candidate genes within the SuprMam1 interval that fit the filtering 
criteria.  Each gene has at least one non-synonymous SNP that differs between the 
C57BL/6 and BALB/c strains.   
 72
 
Primer set name +RT sample QPCR Ct -RT sample QPCR Ct 
Smg1 28.43 No Ct 
Tmc5 37.29 No Ct 
Gp2 No Ct No Ct 
Acsm1 37.53 No Ct 
Dnahc1 36.61 No Ct 
Zp2 38.52 No Ct 
Abca14 No Ct No Ct 
Il4r 26.16 35.15 
Gtf3c1 25.83 No Ct 
Cln3 36.44 No Ct 
Hirip3 26.84 35.95 
 
 
 
 
 
 
 
 
Table 4.3  List of candidate genes that did not amplify in the mammary gland.  
We examined expression of C57BL/6 Trp53+/- MEF RNA using the above 
primer sets.  The Ct values generated by the QPCR Stratagene MxPro software 
are shown using cDNA reactions with Reverse Transcriptase or no Reverse 
Transcriptase controls.   
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CHAPTER 5 
THE ROLE OF THE SUPRMAM1 REGION IN THE IRRADIATION RESPONSE 
OF THE MAMMARY GLANDS  
Introduction 
 The DNA double-strand break repair pathway is fundamental in the prevention of 
breast cancer.  Mutations in genes involved in DNA double-strand break repair lead to an 
increased risk for breast cancer confirming the importance of this pathway in the breast.  
Double-strand breaks are considered the most lethal DNA damage due to the complete 
shearing of the genomic DNA and the lack of template DNA to repair the gap.  The two 
most common causes of DNA double-strand breaks are stalling of replication 
polymerases at sites of damage and exposure to ionizing radiation.  IR can cause DNA 
double-strand breaks by direct energy transfer or by increasing ROS within the cell.  
Numerous studies have demonstrated the effect of IR on breast cancer risk.  Cells that are 
defective in any of the DNA double-strand break repair pathways are sensitive to IR, 
highlighting the its link to breast cancer risk.   
 Identifying genes involved in IR sensitivity have largely been performed in the 
BALB/c mouse strain (Weil et al., 1996; Ponnaiya et al., 1997b; Okayasu et al., 2000a).  
Mori et al. was the first group to use genetic linkage analyses to identify Resistance to 
Apoptosis alleles in thymocytes from BALB/c mice (Mori et al., 1995b).  Rapop1 was 
located in the proximal region of chromosome 16 and was later identified as the gene 
Prkdc, which encodes the NHEJ component DNA-PKcs (Okayasu et al., 2000b).  The 
BALB/c mouse strain has two polymorphisms in DNA-PKcs that appear to affect protein 
expression and end-joining function (Yu et al., 2001c).  In addition, Rapop1 and Tp53 
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appeared to be linked in glucocortocoid induced apoptosis in thymocytes (Mori et al., 
1999).  Other IR-sensitive loci were identified in genetic linkage studies including 
Rapop2 and Rapop3 (Mori et al., 1995a).  Rapop2 was mapped to chromosome 9 with 
DNA damage response gene Atm identified as a viable candidate.  Chromosome 3 
contains Rapop3 with a possible candidate being Mcl-1, a gene belonging in the Bcl-2 
apoptosis family. 
 The BALB/c strain, in addition to IR sensitivity, is prone to IR-induced mammary 
tumors (Butel et al., 1981; Ethier and Ullrich, 1982).  Mammary epithelial cells from 
BALB/c mice have been shown to be susceptible to IR-induced neoplastic transformation 
(Ullrich et al., 1996a).  In addition, these cells showed more IR-induced genomic 
instability(Ponnaiya et al., 1997a).  Finally, mice with the PrkdcBALB/BALB genotype had 
more IR-induced genomic instability in mammary cells than mice with a PrkdcBALB/C57BL 
(Yu et al., 2001d).   
 While this evidence suggests that a defect in DNA-PKcs might explain IR-induced 
mammary tumorigenesis in the BALB/c strain, it does not address the role of spontaneous 
mammary tumors in p53+/- mice.  Mice on a 129/SvJ strain background have the same 
polymorphism in DNA-PKcs as BALB/c, however, they are not prone to spontaneous 
mammary tumors (Mori et al., 2001; Kuperwasser et al., 2000a).  In addition, none of the 
Rapop genes are contained within the SuprMam1 interval, including Prkdc.  Many of the 
studies identifying IR susceptibility alleles were performed in thymocytes.  Because IR 
sensitivity can vary by tissue type, the response in the mammary gland is unclear. 
 Using apoptosis of mammary epithelial cells as a marker, we measured the IR 
response between four strains of mice.  We first tested the IR sensitive and IR resistance 
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strains, BALB/c and C57BL/6, respectively.  We next looked at the first generational 
(F1) cross responses to IR to determine if the IR sensitivity in the BALB/c strain was 
dominant or recessive.  Finally, we generated a congenic strain which consisted of  
C57BL/6 SuprMam1 alleles on a BALB/c strain background.  This allowed us to test if 
there are alleles within the SuprMam1 region that conferred a resistance to apoptosis and 
IR sensitivity.   
Methods 
Mouse surgery and hormonal treatment:: 
Medical grade silastic tubing was cut to a length of 1.2 cm and filled with 50 μg Beta 
estradiol (Sigma) and 20 mg of progesterone (Sigma).  Both ends were sealed with clear 
silicone.  Mice at 9 weeks of age were ovariectomized and allowed one week for any 
endogenous hormones reach baseline levels.  Capsules were implanted subcutaneously on 
the dorsal side of the mouse, ½ inch distal to the neck.  On the fourth day after 
implantation, mice were subjected to 5 Gy ionizing irradiation from a 137Cs source.  Six 
hours later, the mouse was sacrificed and the fourth mammary glands were harvested.  
One mammary gland was fixed in 10% neutral-buffered formalin and the other was flash 
frozen in liquid nitrogen.   
Apoptosis assay: 
Sections of paraffin embedded mammary glands were subjected to TUNEL assay using 
ApopTag Plus Peroxidase In Situ Apoptosis Kit (Chemicon International).  1200 
epithelial cells were counted per slide.   
Generation of BALB.B6-SuprMam1 mice: 
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BALB.B6-SuprMam1 mice were generated by backcrossing mice with C57BL/6 
SuprMam1 alleles on a BALB/c genetic background at least 7 generations (Figure 5.1).  
Primers for the SNP markers used to define the SuprMam1 region include Plekha7 and 
Dock1 which flank the SuprMam1 region.  Internal primers to SNPs within the 
SuprMam1 region were also used for genotyping. 
Results 
The SuprMam1 region does not contain any alleles that affect IR sensitivity 
 Hormones have a clear effect on the IR response within the mammary gland of 
mice (Becker et al., 2005).  To control for this, we ovariectomized the mice and allowed 
seven days for any endogenous hormones to clear before re-introducing hormones by 
capsule implantation (Figure 5.2).  Our results clearly show that the BALB/c strain had 
significantly more apoptosis than the C57BL/6 strain regardless of p53 genotype (Figure 
5.3).  The F1 mice had slightly lower levels of apoptosis than the BALB/c strain, 
although not significant.  The BALB.B6-SuprMam1 congenic strain had similar levels to 
the F1 and was not significantly different than the BALB/c strain.  Apoptosis levels of 
wildtype mice had similar trends to p53 heterozygous mice.    
Discussion 
 The IR sensitivity of the BALB/c strain is well documented.  However, the IR 
sensitivity of the whole mammary gland and the genes involved is less clear.  We 
examined whether there were IR sensitivity differences in the mammary gland of 
different strains of mice.  The purpose was to help establish the idea that there are alleles 
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within the SuprMam1 interval that contribute to IR sensitivity and mammary tumor 
latency.   
 Our results confirm earlier studies showing that the BALB/c strain is sensitive to 
IR-induced apoptosis while the C57BL/6 strain is resistant.  The status of p53 does not 
appear to have a dramatic effect as there were significant differences in IR-induced 
apoptosis between the strains of both genotypes.  The amount of apoptosis in the BALB/c 
p53+/+ mammary gland was surprisingly slightly lower than in the BALB/c-p53+/- gland, 
although not significant.  This was in contrast to a study showing diminished apoptosis in 
p53+/- mice.  We did not test IR sensitivity in p53 null mice due to the necessity of p53 in 
mammary gland apoptosis.  The F1 mice were also tested for their IR sensitivity and 
showed a slight decrease in apoptosis compared to the BALB/c strain without being 
significant.  Because multiple genes are involved in IR-sensitivity in the BALB/c strain 
(Rapops1-3), it is much more difficult to interpret this data.  IR-sensitivity appears to be a 
dominant trait since the F1 apoptosis levels were not significantly different than the 
BALB/c.  
 Finally, we generated a congenic strain as described in Figure 1.  The apoptosis 
levels from the BALB.B6-SuprMam1 strain were not significantly different from the 
BALB/c suggesting there are no significant alleles that contribute to IR sensitivity within 
the SuprMam1 region.  This was not totally unexpected since previous studies did not 
detect any obvious IR sensitivity alleles within this region (Blackburn et al., 2007a).  
Almost all breast cancer risk alleles play a prominent role in the DNA damage and DNA 
dsb repair response.  Cells defective in these pathways are sensitive to IR.  Our data 
suggests that the gene or genes responsible for decreased spontaneous mammary tumor 
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latency in the BALB/c strain is not likely involved in the aforementioned pathways.  
More importantly, this data eliminates Palb2 as a likely candidate due to its location 
within the SuprMam1 interval as well as the observation that cells defective in Palb2 are 
sensitive to DNA damaging drugs (Zhang et al., 2009c).  This experiment measured the 
amount of apoptosis as an indicator of proper DNA double-strand break repair in the 
mammary gland.  Thus, it is possible any difference observed between the strains is due 
to a gene involved in the apoptosis pathway.  It is also possible that any effect from a 
gene within the SuprMam1 interval is being masked from other genes within the genome 
of the BALB.B6-SuprMam1 congenic strain.  This is not unfeasible as multiple genes are 
involved in the DNA damage response in addition to the apparent IR-sensitivity 
dominance in the BALB/c strain.   
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C57BL/6 SuprMam1
BALB/c X C57BL/6
F1 X BALB/c
X9
BALB.B6-SuprMam1 strain
Chromosome 7
Figure 5.1  Flow chart describing the strategy in creating the congenic strain.  The F1 
mice were backcrossed at least 9 times, keeping the C57BL/6 SuprMam1 region intact.  
After ten generations, the background genetic identity would be 98.5% BALB/c (Silver, 
1995). 
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8 weeks of age
Ovariectomized
7 days later
E+P silastic tube 
implanted
4 days later
Irradiated with 5 gy
6 hours later
Animal sacrificed, 
mammary glands 
harvested
4 hours later
Injection of BrdU
Time (not to scale)
Procedure
Figure 5.2  Timeline protocol for harvesting mammary glands to perform 
TUNEL apoptosis assays. 
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Figure 5.3  Irradiation induced apoptosis in the mammary gland.  At least 1200 epithelial 
cells were counted per mammary gland.  The percentage of positive cells (brown) are 
graphed with the number of mice at the bottom of each bar.  (A)  TUNEL positive cells in 
mammary glands from mice on a p53+/- background.  Students t-test, significance *p<.05.  
(B)  TUNEL positive cells in mammary glands from mice on a p53+/+ background.  Students 
t-test, significance *p<.05  
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 CHAPTER 6 
SUMMARY 
 These studies have attempted to identify the genes and pathways responsible for 
the increased mammary tumor susceptibility in the BALB/c-Trp53+/- mouse strain.  
Identification of these genes and pathways could lead to further insights into breast 
cancer detection and treatment.  In addition, this model provides the means to identify 
new low penetrance modifiers to breast cancer susceptibility. 
 We first tried to establish differences in DNA repair between our spontaneous 
mammary tumor susceptible strain, BALB/c-Trp53+/-, and our resistant strain, C57BL/6-
Trp53+/-.  Using a novel DNA double-strand break repair assay developed by the 
Wiesmüller lab, we were unable to establish clear differences in DNA repair.  This was 
due to inconsistent results from experiment to experiment.  We next employed an 
immunofluorescence assay that allows the observation of proper localization of DNA 
repair proteins following DNA damage.  We observed a significantly decreased 
localization of RAD51 in the BALB/c MEFs following irradiation.  This indicates a 
possible signaling defect in the BALB/c strain that occurs after the initial DNA damage 
response as no difference in H2AX signaling was observed.  Cells that are defective in 
DNA repair are sensitive to DNA damaging agents.  Specifically, cells defective in any 
Fanconi Anemia component, (eg. BRCA2, BRIP1, PALB2) show heightened sensitivity to 
MMC and Camptothecin (Patel, 2007).  Our results suggest no defects in any of these 
components as sensitivity to these drugs were not significantly different between the 
strains.   
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 Finally, we employed the comet assay, a more robust and generalized assay that 
established clear differences in DNA repair between the strains.  First, we observed clear 
differences in initial damage before repair has begun in the BALB/c strain.  Second, 
BALB/c-Trp53+/- MEFs demonstrated significantly more damage over time following 
irradiation.  Third, we observe significantly more DNA damage in the BALB/c strain 15 
hours post-irradiation, the window when HRR is the predominant repair pathway.  We 
see similar increases in damage after Camptothecin treatment in BALB/c MEFs as well.  
Finally, treatment with Vanillin, a specific inhibitor for NHEJ component DNA-PKcs, did 
not change the significant amounts of damage observed between the strains.  This 
suggests the increased irradiation-induced damage observed in the BALB/c strain is not 
due to its inherent defect in DNA-PKcs.   
 The BALB/c strain has a clear defect in the NHEJ pathway due to a SNP in DNA-
PKcs.  However, our results suggest that this strain may also have other defects 
independent of the NHEJ pathway.  First, we chose a timepoint of 15 hours to measure 
the amount of irradiation-inducing damage which is much later than the one or two hour 
window that NHEJ occurs post DNA damage.  Second, we specifically inhibited DNA-
PKcs and show that there is still increased damage in the BALB/c strain suggesting this 
protein is not a factor at this timepoint.  We also observed an increase in damage 
immediately following irradiation suggesting the BALB/c strain may be sensitive to the 
actual damage due to increased ROS (Halliwell and Gutteridge, 1984b).  Our 
immunofluorescence data suggests a defect in HRR signaling as RAD51 localization was 
decreased in the BALB/c strain.  What signaling pathways may be responsible for this is 
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unknown, however, the ATM DNA damage response pathway is a viable target 
(Bartkova et al., 2005). 
 The SuprMam1 linkage mapping provided us powerful tools to identify genes 
responsible for mammary tumor susceptibility in the BALB/c strain.  Searching for genes 
involved in DNA repair and breast cancer susceptibility identified Palb2 as a candidate 
gene localized in this region.  Subsequent gene expression analysis demonstrated no 
difference between the strains.  In addition, no coding SNPs were identified between the 
strains effectively eliminating this gene as a candidate. 
 Further narrowing of the interval with additional markers as well as a filtering 
criteria produced a list of 34 candidate genes.  Gene expression analyses were performed 
and identified Il21r as a gene significantly more highly expressed in the BALB/c strain.  
Unfortunately, this same gene was significantly overexpressed in the BALB.B6-
SuprMam1 congenic strain suggesting the activation of this gene lies outside the 
SuprMam1 region eliminating it as a candidate.  The inability to identify any candidate 
genes with significantly different gene expression between the strains was disappointing.  
However, the possibility remains that any of the coding SNPs in the candidate genes may 
effect the function of the corresponding protein and possibly increase mammary tumor 
susceptibility.  This was the case in genes involved in double-strand break repair whose 
SNPs were linked to breast cancer (Goode et al., 2002).  It remains to be seen if this is the 
case or perhaps another gene outside of our list of candidates but contained within the 
SuprMam1 interval is a better candidate. 
 Finally, we were interested in determining if there were any irradiation sensitivity 
alleles within the SuprMam1 region.  To test this, we measured irradiation-induced 
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apoptosis in the mammary gland of various strains including C57BL/6, BALB/c, F1 and 
BALB.B6-SuprMam1.  Our results recapitulate previous work showing the BALB/c 
strain being sensitive to irradiation.  We also concluded that there does not appear to be 
any irradiation sensitivity alleles within the SuprMam1 region as no differences in 
apoptosis were observed between the BALB/c strain and the BALB.B6-SuprMam1 strain.   
 We have established a defect in RAD51 localization to DNA double-strand breaks 
following DNA damage suggesting an error in this pathway.  This defect in addition to 
the defect in NHEJ present in the BALB/c strain may predispose to increase mammary 
tumor susceptibility.  It appears likely that either our filtering criteria was too stringent or 
that the function of one of our candidate genes is diminished by a coding SNP.  In 
addition, the possibility exists for other non-coding elements within the SuprMam1 
region may be affecting mammary tumor susceptibility in the BALB/c strain.  Future 
work will need to be done to address these hypotheses.                   
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CHAPTER 7 
PROTOCOLS 
Double-strand break DNA repair Assay 
 
List of equipment:  
 AMAXA Nucleoporator  
 FACS tubes 
Alpha MEM media (Gibco) + 10%FBS + additions (glutamine, BME, antibiotics) 
   PBS + 0.2% EDTA 
   Plasmids:  J04-38 wt-EGFP control plasmid 
       J04-39  NHEJ construct plasmid 
       J04-40 HR-3’ construct plasmid 
 
 
Prepare Cells 
a. Friday before: 
i. Thaw 2 vials of passage 0-3 MEF cells of each desired cell line 
into 2 T-75 flasks using 10ml/ flask Alpha mem medium with all 
additions 
ii. Let grow over the weekend 
b. Monday before experiment 
i. Trypsinize cells and count 
ii. Seed 3 x 106  into 4 T-75 flasks with 10 ml/ flask DMEM/F12  
medium + all additions 
iii. Freeze left over cells if necessary 
c. Thursday (the day of the experiment) 
i. Trypsinize cells ( 2 ml trypsin, when cells come up add 2 ml D/F 
medium + 10% FBS 
ii. Count cells  
iii. Spin in a 50 ml conical; remove supernatant 
iv. Dilute with PBS  so that cells number 8 x 105  / ml 
v. Add 3 ml / 15 ml conical for a triplicate electroporation ( e.g. for 
testing HR in triplicate) 
vi. Generally 4 tubes / cell line: 
A. 5 ml in 15 ml conical for 2 control and 3 NHEJ 
electroporations 
B. 3ml in 15 ml conical for 3 HR electroporations 
C. 3ml in 15 ml conical for 3 GFP electroporations 
D. 3 ml in 14 ml conical for extra cells in case of mistake 
vii. Spin tubes 5 min 200 x g, aspirate supernatant and put pellet on ice 
Electroporation 
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d. Remove one 15 ml conical from ice and remove any excess PBS from pellet 
with P200 set at 100 
e. Resuspend pellet in  310 ul room temperature AMAXA solution ( pipette up 
and down gently – no bubbles) 
f. Remove caps from 3 cuvettes and place caps upside down in front of the 
cuvettes.  
g. In the cap, place 5.1 ul of the plasmid mixture. 
h. Remove 100 ul of cells from the resuspended solution and mix with plasmid 
in the cap;  place suspension of cells + plasmid into cuvette. 
i. Using same pipette tip, mix the remaining cells, 100 ul at a time with the 
plasmid in the cap and place in cuvette;  cap all cuvettes 
j. Electroporate with program A23 in Nucleoporator 
k. Remove the 6 well plate and the 60 ml dish from the incubator 
l. Remove caps from cuvettes and add 0.5 ml D/F medium + additions to each 
cuvette 
m. Using transfer pipette transfer cells electroporated  with plasmid from 1 
cuvette to 1 well of 6 well plate.  Rinse cuvette with medium taken by 
transfer pipette from a different part of the well. 
 
 
FACS Set-up 
 
-Open up 2 dot plots on the global worksheet (right screen) and one histogram 
 
-Click the Parameters tab under Instrument Settings in the Browser Window 
 
-Change FITC to GFP and delete everything except:   FSC, SSC, GFP, PE 
 
-GFP: LA 
PE: LA 
All others have area 
 
-Switch windows accordingly:    
 
 
 
 
 
 
 
 
 
 
 
SSC-A 
GFP 
PE-A 
FSC-A  
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Count  
 
 
 
 
 GFP  
 
-Change Voltage in Instrument Window:  FSC: 340 
            SSC:  285 
            GFP:  430 
            PE:  401 
-Record 50,000 events:  Experiment Layout, acquisitions to 50,000 
 
 
Comet Assay 
 
Solutions: 
 
Lysing Solution: Ingredients per 1000 mL: 2.5 M NaCl 146.1 gm 
100 mM EDTA 37.2 gm 
10 mM Trizma base 1.2 gm 
 
Add ingredients to about 700 mL dH2O and begin stirring the mixture. Add ~8 gm 
NaOH 
and allow the mixture to dissolve (about 20 min). Adjust the pH to 10.0 using 
concentrated 
HCl or NaOH. q.s. to 890 mL with dH2O (the Triton X-100 and DMSO will increase the 
volume to the correct amount), store at room temperature. 
 
Final lysing solution: add fresh 1% Triton X-100 and 10% DMSO, and then refrigerate 
for 
at least 30 minutes prior to slide addition. 
 
NOTE: The purpose of the DMSO in the lysing solution is to scavenge radicals generated 
by 
the iron released from hemoglobin when blood or animal tissues are used. It is not needed 
for 
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other situations or where the slides will be kept in lysing for a brief time only. 
 
Electrophoresis Buffer (300 mM NaOH / 1 mM EDTA): 
Prepare from stock solutions:  
1. 10 N NaOH (200 g/500 mL dH2O) 
2. 200 mM EDTA (14.89 g/200 mL dH2O, pH 10) 
 
Store both at room temperature. We prepare the NaOH and EDTA stock solutions every 
~2 
weeks. 
 
For 1X Buffer (made fresh before each electrophoresis run): per liter, add 30 mL NaOH 
and 
5.0 mL EDTA, q.s. to 1000 mL, mix well. The total volume depends on the gel box 
capacity. 
Prior to use, measure the pH of the buffer to ensure >13. 
 
Neutralization Buffer: 0.4 M Tris - 48.5 gm added to ~800 mL dH2O, adjust pH to 7.5 
with 
concentrated (>10 M) HCl: q.s. to 1000 mL with dH2O, store at room temperature. 
 
Staining Solution:  DAPI at a concentration of 0.1 µg/mL in PBS.  Stock is 500 µg/mL, 
do a 1:5000 dilution. 
 
Procedure: I typically add 100,000 cells per 60 mm plate and process the next day.  
Depending on your cell type, you may have to adjust. 
 
1. The day before running the assay, prepare slides by dipping in methanol and 
flaming them to remove oil layer on slide.  Next, dip slides into beaker with 
1% normal agarose (recommended 50 mL of agarose diluted in water in 250 
mL beaker).  You may have to flame the slides further for agarose to coat 
slides properly.  Wipe off bottom and place in dust free area to cool overnight. 
 
2. The day of the assay, trypsinize cells off plates, neutralize trypsin with media 
plus serum and spin down cells.  Remove media leaving pellet.   
 
3. Resuspend cells in 10 µl PBS. Add 75 µl of 0.5% low melting agarose (made 
with PBS) to tube and pipet up and down to mix.  Pipet mixture on pre-coated 
slides and carefully place coverslip on top.  Place slides in 4 degree for 5 min.   
 
4. Take out slides from fridge and carefully remove coverslips.  Pipet another 80 
µl of 0.5% low melting agarose on top of slides and place coverslips back on.  
Place slides back in 4 degrees for 5 more minutes. 
 
5. Remove slides from fridge and remove coverslip carefully.  Place slides 
vertically in coplin jars with ~25 mL of lysis buffer or enough to cover 
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6. Remove slides from coplin jars and place in electrophoresis box with just 
enough buffer to cover slides.  Make sure the agarose part of the slide faces or 
is closer to the cathode (red or positive end).  Let the slides sit in the box with 
buffer for 20 minutes to allow DNA to unwind. 
 
7. Electrophorese the slides at 24 volts and 300 mAmps.  Adjust buffer volume 
to achieve 300 mAmps while keeping 24 volts constant.  Run slides for 30 
minutes. 
 
8. Remove slides from electrophoresis box and add ~750 µl of neutralization 
solution to slides.  Allow slides to sit for 5 min. at RT.  Repeat procedure 2 
more times.  After last incubation, wash slides gently with dH2O (by pipetting 
or squirt bottle).   
 
9. Add ~750 µl of DAPI to slide and incubate 5 min. at RT.  Wash off excess 
DAPI with dH2O and place coverslip on top of slide.  Place slides in dark or 
analyze. 
 
MEF Immunofluorescence 
Materials:  
 Cell culture plates 
 MEF media 
 PBS 
 Formaldehyde 
 Triton X-100 0.5% 
 Tweezers 
 Round microscope coverslips 
 12-well plate 
 Goat Serum 5% 
 Primary and Secondary anti-bodies 
 Mounting solution (recipe in protocol) 
 DAPI stain (0.1 µg/mL in PBS) 
  
 
1. Irradiate plates using the gamma irradiator 
2.  Incubate 37 degrees for appropriate timepoint. 
3. Remove media and wash cells once with PBS. 
4. Add 500 μl of 3.7% formaldehyde for 7 minutes to fix cells. 
5. Remove formaldehyde and wash cells 2 times with PBS. 
6. Add 500 μl of .5% TritonX in PBS to the cells for 7 minutes on ice. 
7. Remove TritonX and wash cells once with PBS. 
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8. Using tweezers, carefully remove coverslips from wells and dip in PBS/.05% 
Tween before placing coverslip on an upside down top of a 24-well plate with the 
cells facing up. 
9. Add 25 μl of primary antibody diluted in PBS with 5% goat serum to coverslip.  
10. Cover and either incubate 37 degrees for 1 hour or 4 degrees overnight. 
11. Place coverslips back into 24 well plate and wash coverslips 3 times, 5 minutes 
each. 
12. Dilute secondary antibody in PBS with 5% goat serum and add 25 μl to each 
coverslip on upside down top of a 24 well plate as described in step 9. 
13. Incubate 30-45 minutes at 37 degrees. 
14. Place coverslips back into 24 well plate and wash coverslips 3 times, 5 minutes 
each. 
15. Dilute DAPI in PBS and incubate coverslips in 250 μl for 5 minutes. 
16. Wash coverslips 2 times with PBS. 
17. Mounting solution composes of 3 parts Mowial(Calbiochem) and 1 part DABCO 
(Sigma). 
18. Place a drop of mounting solution on glass slide, then carefully place coverslip 
with cells facing down onto slide. 
19. Cover slides (protect from light) and let sit overnight. 
20. Next day, wash salt off slides with deionized water and wait 1 hour to dry. 
21. Capture pictures of cells using a fluorescence microscope. 
 
Mounting Agent Recipe 
 
1. Put 6 grams glycerol in 150 ml glass beacker and add a small stir bar 
2. Add 2.4 g Mowiol (Calbiochem); stir to mix 
3. While stirring, add 6 ml distilled water and leave for 2 hours at room 
temperature 
4. Add 12 ml 0.2M Tris (pH 8.5) 
5. Incubate the tube in hot water (50-60oC) for 10 minutes to dissolve the 
Mowiol.  This can be repeated over several hours if necessary. 
6. Centrifuge at 5000 g for 15 minutes to remove any undissolved solids.  Store 
1 ml aliquots in eppendorf tubes at -20 oC. 
7. Warm tubes to room temperature for use.  Opened tubes can be stored at 4 oC 
for approximately 1 month.   
 
Mouse Ovariectomy 
Equipment:   
  Hair clippers 
  Surgical scissors 
  Surgical forceps 
  Serrifin clamps 
  Ethicon sutures 6-0 gauge 
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  Wound stapler 
  9mm stainless steel wound clips 
  1 mL 26G syringes (Becton Dickinson) 
  70% ethanol 
  Avertin (.02g/mL) 
   
   
Procedure: 
1. Shave the back of the mouse. 
2. Make a single mid-line incision along the back. 
3. Lay the mouse on its side and locate one ovary.  The ovary is beneath a 
deposit of white fat that is quite apparent in contrast to the surrounding 
dark red organs.  Make an incision through the peritonium and pull the 
ovary out using the sharp jewlers forceps (#6).  Note that the kidney can 
be easily damage because it is attached to the ovary by loose tissues. 
4. Use the Serrifin clamp to hold the ovary.  Place a ligature at the base of 
the ovary, but try to remain above the Fallopian tubes.   
5. Remove the ovary, then close the peritoneum with one or two stitches. 
6. Repeat the procedure on the contralateral side. 
7. Close the skin with 2-9 mm wound clips. 
 
MEF isolation 
Materials:   
 
 Uterine Rinse: 
  125 ml Phospate Buffered Solution 
2 ml  AB/AM (100U/ml penicillin, 100 μg/ml streptomycin, .25 μg/ml 
amphotericin final) (Gibco 100X) 
  1 ml Fungizone 
  0.5 ml Tylosin tartarate (Gibco) (8 μg/ml final concentration) 
  30 μl Gentamycin (Gibco) (15 μg/ml final concentration) 
 
 Collagenase solution: 
  0.1 g Collagenase (Gibco) 
  50 ml Alpha MEM media (Fisher Scientific) 
  10 μl Gentamycin 
  0.25 ml AB/AM 
  0.25 Fungizone 
  0.25 Tylosin  
 
 Medium: 
  500 ml Alpha MEM 
  50 ml Fetal Bovine Serum (FBS) 
  5 ml AB/AM 
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1.4 ml Beta mercapto ethanol (Gibco 1000X) 
5 ml Glutamine (Gibco 100X) (2mM final concentration) 
150 μl Gentamycin 
.5 ml Tylosin 
 
Procedure: 1.  Mate animals, check for plugs to confirm mating 
  2.  Sacrifice pregnant mouse 14 days after plug confirmation 
  3.  Collect uterus of p14 mouse in 100mm dish of uterine rinse solution 
  4.  Transfer uterus to clean 100mm dish of sterile uterine rinse 
  5.  Using forceps, gently tear the uterine walls so that fetus pops out 
  6.  Remove head of fetus and any internal organs that appear a crimson red 
  7.  Transfer bodies to a clean 100mm dish 
               8.  When done with all fetuses, place each individual in a clean 60mm dish 
with uterine rinse. 
 9.  Transfer all material to tissue culture hood.  Aspirate rinse and mince     
     each fetus separately with scissors. 
10. Add 2 ml of 0.2% collagenase (Worthington Collagenase type 3, 0.1 g        
in 50 ml Alpha MEM media without serum but with appropriate          
antiobiotics. 
11. Transfer minced fetuses each to a 15 ml conical tube and incubate 30                
minutes at 37oC.  Every 10 minutes, gently invert tubes.  Do not 
overdigest. 
  12.  Pellet cells by centrifugation at 1200xG for 5 minutes 
  13.  Wash pellet with Alpha MEM media no serum 
           14.  Resuspend pellet and plate on a T-75 plate with Alpha MEM complete 
media. 
 
Hormone filled silastic tubing capsules and Implantation 
 
Reagents: 
 Medical grade silastic tubing (Dow Corning, 508-009) 
 Clear silicone 
 Beta Estradiol 50 μg/tube (Sigma, E2758-1G) 
 Progesterone  20 mg/tube (Sigma, P0130-25G) 
 Wound Clips 
 Hair clippers 
 Scissors, forceps 
 Avertin ( 
 
II. Preparation 
A. Silastic tubing (can be autoclaved if sterility is an issue) 
1) Cut silastic tubing the length of 1.2 to 1.5 cm 
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2) Seal one end of the tubing with clear silicone. Squeeze silicone on end of 
tubing and scrape off any extra, being sure the end is completely sealed. 
Allow to dry 2 to 3 hours. 
 
B. Prepare steroid stock   
1) Master mix – prepare enough master mix for double the amount of samples 
you have (ex. for 4 mice make enough MM for 8)  
2) Weigh out hormones on the small balance, see dosage column above. (ex. if I 
had  4 mice I and wanted to treat them with Progestrone I would multiply 
8(because we double the amount of samples) by 400ug. This would be .003g. 
3) If treating with a combination of hormones, weigh the hormones individually. 
Then stir them together well in a small beaker with a spatula 
4) Cut the end of a 5ml pipette to use for a funnel and insert it into the open end 
of the capsule.  
5) Weigh the capsule prior to filling and pack with 20-30mg of hormone master 
mix. As the master mix is being added use the wooden end of a swab to pack 
the hormones in. 
6) Seal opposite end if the tubing. Let silicone set 2 to 3 hours. 
7) After 2 to 3hrs incubate capsule at 37C overnight in PBS, the next day 
implant. 
 
C. Implantation   
1) Keep capsules in PBS until implantation. 
2) Prepare the area by shaving the dorsal region of the mouse. Make an incision 
through the skin over the shoulders. Implant subcutaneously. Close with a 
wound clip. 
RT and QPCR reactions 
Total RNA was isolated using Trizol solution according to protocol.  Isolated RNA was 
reverse transcribed using Stratagene cDNA kit  and analyzed for gene expression using 
Stratagene Syber Green kit.    
cDNA protocol: 
1X 
10 ul Master Mix 
1.5 ul Random Hexamer primers 
1.5 ul oligo dT 
3 ul dH2O 
3 ul of RNA (1ug total) 
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Mix random hexamer primers, olido dT and RNA together and incubate at 65 degrees for 
7 minutes.  Then add master mix and 1 ul Reverse transcriptase in RT samples.  Incubate 
at 50 degrees for 45 minutes then 85 degrees for 10 minutes. 
 
This cDNA is then diluted 1:5 and 1 ul is used for each sample in a QPCR reaction. 
 
 
QPCR reaction: 
 
1X 
10 ul Master Mix 
8 ul dH20 
.2 ul F primer (50 pm/ul) 
.2 ul R primer (50 pm/ul) 
1 ul cDNA reaction 
 
Basic reaction conditions, primer Tm is 58 degrees for 45 seconds and then extension at 
72 degrees for 45 seconds. 
 
SM1 genotyping protocols 
 
PCR mix 
1 reaction 
dH2O           21.8 μl 
Thermopol buffer (Roche)                   2.7 μl 
dNTP mix (Roche)   1.09 μl 
Primer set (F and R)(50 pm/ μl each) 0.45 μl 
              26.04 μl 
 
Enzyme Mix 
1 reaction 
dH2O                4 μl 
Thermopol buffer (Roche)                   0.5 μl 
Taq polymerase (Roche)                       0.5 μl 
                     5 μl 
 
1.  Add 1ul of DNA aprox .08-2ug/ul to 26ul of MM, add  
2.  Add 5ul of EM for each RX 
 
Thermocycler conditions: 
95C 8min 
95C 30 Sec 
57C 45 sec 
72C 1min 
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Go to 2 35X 
72C 10 min 
4C forever  
 
Restriction Enzyme digestion: 
 
1 reaction 
dH2O     12 μl 
Restriction enzyme buffer (NEB) 3 μl 
Restriction enzyme    1.5 U 
BSA (if needed)   0.3 μl 
 
1. Add 15ul of digest mix to 15ul of the PCR product and incubate at 37C for 3hr.  
2. 2.  Make a 2% TBE gel with ethidium bromide and run the digested amplicon at 
150 volts.  Take a picture of the gel and analyze bands.   
 
 
Apoptosis Assay 
 
TdT-FragELTM DNA Fragmentation Dectection Kit (TUNEL) (Calbiochem QIA33)  
Cut 4mm mammary gland sections and put on slide warmer the night before 
TUNEL assay.  Maximum number of slides one can effectively use is 12-14.  During 
assay do not ever let tissue dry out.  Store in 1X PBS when necessary. 
1.  Prior to beginning assay do the following: 
a. Prewarm incubator and water bath to 37oC 
b. Defrost on ice 
i. Proteinase K 
ii. 5X TdT equilibration buffer 
iii. TdT labeling reaction mix 
c. Prepare 10mM Tris, pH 8.0 
i. 100l of 1M Tris, pH 8.0 in 9900l 
MQH2O 
d. Prepare 1X TBS 
2. Deparaffin and rehydrate tissue (prepare ProK during rehydration steps) 
a. 3 X 5 minutes in Xylene 
b. 2 X 5 minutes in 100% EtOH 
c. 1 X 3 minutes in 95% EtOH 
d. 1 X 3 minute in 70% EtOH 
e. 1 X 5 minute in PBS 
3. Permeabilization of specimen 
a. Prepare 20μg/mL 1:100 Pro K in 10mM Tris, 
pH 8.0 
b. Example:  14 + 1 specimens = 15l of Pro K 
and 1485l of 10mM Tris, pH 8.0 
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c. Do slides one at a time.  Start the timer at 12 
minutes after the very first slide.  When 
complete note the time remaining on the timer 
and calculate average time in seconds for 
draining Pro K from slides so all slides have 
equal exposure time.   
d. Drain TBS from slide and wipe around tissue 
e. Add 100l of 10g/ml Proteinase K 
f. Incubate 12 minutes (Prepare PBS/H2O2) 
g. When complete, put slides in fresh dH2O 2X for 
2 minutes each. 
4. Inactivation of endogenous peroxidases 
a. Make PBS/H2O2  of 180ml PBS plus 20ml of 
30% H2O2 
b. Drain PBS from slide 
c. Put slides in slide jar with PBS/H2O2 
d. Incubate 5 minutes at RT – DO NOT OVER 
INCUBATE (Prepare TdT buffer) 
e. Transfer slides back to PBS 2X for 5 minutes 
each. 
5. Equilibration 
a.  Tap off excess liquid, wipe around tissue 
b. Add 75l of TdT equilibration buffer 
c. Incubate 10 minutes (prepare labeling reaction 
mix after 10 minutes)  
6. Labeling 
a. Prepare microfuge tube with 77 μl reaction 
buffer (6 tubes for 12 samples) 
b. Work with two slides each time 
c. Tap off excess liquid, wipe around tissue 
d. Add 33 μl of TdT enzyme to microfuge tube. 
e. Add 50 μl of diluted TdT enzyme to tissue, seal 
top cover with parafilm 
f. Add hot sponges to humidity chamber 
g. Incubate 1 hours at 37oC 
7. Termination of Labeling 
a. Prepare ~100 mL of working strength stop/wash 
buffer- 3mL stop/wash + 102 H2O 
b. Put stop/wash buffer in coplin jar, add slides 
c. Incubate agitating for 15 seconds 
d. Incubate 10 minutes at room temperature 
8. anti-digoxigen conjugate 
a. Wash specimen 3X in PBS one minute each 
b. Tap off excess liquid and wipe around the tissue 
c. Apply room temperature anti-digoxigen to 
tissue ~65 μl 
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d. Cover slides with square piece of parafilm 
e. Incubate at room temperature in humidity 
chamber with sponges for 30 minutes 
9. Develop color in peroxidase substrate 
a. Wash slides in 4 changes of PBS at room 
temperature, 2 minutes each 
b. Add 147 μl of DAB dilution buffer plus 3 μl 
DAB substrate (enough for 2 slides) 
c. Tap off liquide and wipe around tissue 
d. Cover tissue with 75 μl of peroxidase substrate 
e. Stain for 5 minutes 
10. Counterstain 
a. Wash specimen 3X in dH2O one minute each 
b. Incubate slides in dH2O for 5 minutes at room 
temperature 
c. Counterstain with hematoxylin for 20 seconds 
d. Rinse in hot water 
e. Incubate in glacial acetic acid for 20 seconds  
f. Incubate in ammonia water for 15 seconds 
g. Dehydrate in classic 95%, 100%, xylene run 
through, 3 minutes each. 
h. Mount specimen with permount and coverslip, 
allow slides to dry overnight 
 
Solutions for cell culture 
 
 2X Freeze media 
  40 ml desired media (DMEM:F12 with 10% FBS) 
  10 ml DMSO (5ml glass vials of Dimethyl Sulphoxide) 
  Store at -20oC in 10 ml aliquots 
 DMEM:F12 Media 
  1 bottle of DMEM:F12 powered media 
  1.2g NaHCO3  sodium bicarbonate 
  2.38g of HEPES 
  Bring volume up to ~ 800 ml with MQ H2O 
  Adjust pH to 7.6 
  Filter sterilize into 2 – 500ml bottles 
  Store at 4oC  
 Add to DMEM:F12 media before use (500ml bottle) 
  10% heat treated (30 minutes at 55oC) FBS  50ml 
  L-glutamine       5ml 
  Bins (bovine insulin)     500l 
  Gentamycin      150l 
  AB/AM        5ml 
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Mouse tail DNA isolation 
 
1. 0.5-1 cm mouse tail to be genotyped in 1.5 ml Eppendorf tube 
2. Add 0.5 ml TENS buffer to tube (100 mM Tris-HCl pH 8.5; 5 mM EDTA; 
0.2% SDS; 200 mM NaCl) 
3. Add 5 μl of stock 10 mg/ml proteinase K (100X) to 100 μg/ml final 
4. Vortex and incubate overnight at 55Co in water bath or hybe-oven 
5. Next day, vortex and centrifuge 13K RPM at room temperature for 5 
minutes.  Transfer supernatant to a new tube. 
6. Add 0.5 ml isopropanon; invert and shake tubes until DNA precipatates 
7. 3 options: 
a. Centrifuge 5 min. 13K RPM 
b. Pick DNA precipitate with pipette tip and transfer to clean 
tube 
c. Hold the DNA precipitate on side of tube and decant 
supernatant 
8. Wash DNA precipitate with 70% ethanol, centrifuge for 5 minutes at 13K 
RPM 
9. Remove liquide and dry tubes upside down for 5 minutes and vacuum dry 
for 5 minutes or air dry an additional 30 minutes. 
10. Add 50 to 100 μl TE (Tris-EDTA) and solubilize for 2 hours to overnight at 
37-65C.  Vortex. 
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APPENDIX A 
PALB2 SEQUENCING RESULTS 
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Appendix A notes:  Alignment of Palb2 sequencing.  “Palb2 mRNA” is the 
established coding sequence of Palb2.  First two numbers of each sequence 
correspond to the following:  C57BL/6-Trp53+/- samples include 15, 17 and 19 
while BALB/c- Trp53+/- samples include 1, 5 and 8.  Second group of 
numbers/letters indicate sequencing primer used (sequence for primers in 
methods).  “rc” stands for reverse compliment.  “Contig 4” indicates the consensus 
sequence.  Dots below the consensus sequence indicate different bases among the 
alignment while a “+” sign indicates a space or miscall. 
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APPENDIX B 
IMMUNOFLUORESCENCE IMAGES 
Appendix B notes:  Examples of immunofluorescence images.  Co-
localization of RAD51 and γ-H2AX with DAPI nuclear stain.  Images 
consist of 3 images overlayed at the following wavelengths:  488 nm 
(RAD51), 594 nm (γ-H2AX) and 350 nm (DAPI). 
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